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Abstract

TELOMERE LENGTH IN WOMEN WITH BREAST CANCER: A LONGITUDINAL STUDY
OF THEIR RELATIONSHIP TO CHEMOTHERAPY AND ACQUIRED
PSYCHONEUROLOGICAL SYMPTOMS
Areej Abdulaziz Alhareeri, PhD
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2016
Director: Colleen Jackson-Cook, PhD
Professor
Department of Pathology

Breast Cancer (BC) is one of the most commonly diagnosed malignancies in females. The 5-year
survival rate for women with early stage BC is about 90%. However, the quality of life (QOL)
for many of these women may be adversely affected due to treatment/cancer–related side effects,
including a constellation of symptoms (anxiety, depression, pain, fatigue, sleep disturbance and
depression), that are collectively termed psychoneurological symptoms (PNS). To gain insight
into the contributory role of telomere length (TL) in the development and persistence of PNS, we
have longitudinally studied 72 women (ages 23-71) with early stage BC (I-IIIA) at 5 time points:
prior to chemotherapy (baseline), prior to the fourth cycle of chemotherapy (mid-chemo), 6
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months, 1 year and 2 years following the initiation of chemotherapy. Measures quantified
included TL [using both a monochrome multiplex qPCR assay (at 5 time points) and a semiquantitative chromosome-specific fluorescence in situ hybridization (FISH) assay (at baseline
and mid-chemo)] and scores for each PNS. Variables predictive of qPCR mean TLs were age
(p=0.004) and race (African Americans had greater mean TLs than Caucasians; p=0.019). While
visit was not found to be a significant predictor of mean TLs (p=0.666), chromosome-specific
TL shortening was observed at mid-chemo for 1p (p =0.022), 5q (p = 0.041), 7q (p =0.025), 9q
(p =0.045), 18q (p =0.002), 20p (p =0.020), 21q (p =0.040) and 22p (p =0.025). Type of
chemotherapy was shown to be a significant predictor of both mean TLs (TAC significantly
greater than TCH; p= 0.036) and chromosome-specific TLs for 32 of the 46 chromosomal arms
(p=0.004 to 0.049). Pain was found to be a significant negative predictor of chromosomespecific TLs (higher pain; shorter telomeres) for 5q (p=0.040), 8p (p=0.047), 13p (p=0.019), 20p
(p=0.036), 22p (p=0.035), Xp (p=0.014), Xq (p=0.039). Expanding upon the knowledge gained
from this study offers hope for the future development of biomarkers that could identify patients
at risk for PNS and improve their QOL.

	
  

Chapter 1
General Background

Breakthroughs in Early Telomere Research
Telomeres were first described in the 1930s by Hermann Muller and Barbara McClintock,
through their studies in Drosophila (Muller, 1938) and maize (McClintok, 1941), as special
structures at the end of chromosomes required for their integrity. Muller first coined the term
“telomere” and three years later, McClintock (1941) proposed that telomeres stabilize
chromosome ends and prevent them from being recognized as DNA double strand breaks.

In 1961, Leonard Hayflick and Paul Moorhead developed a theory that cells cultured in vitro
were not immortal, but could replicate only a finite number of times, a phenomenon now known
as replicative senescence or the the “Hayflick limit”, and suggested the existence of a cellular
counting mechanism (Hayflick & Moorhead, 1961). Furthermore, they observed the presence of
two broad classes of cells, normal mortal cell strains and immortal cancer cell lines (reviewed in
Hayflick, 1998). Their discovery challenged a central dogma of the time that supported the belief
that cultured cells would divide indefinitely in vitro, with any culture failures being attributable
simply to a lack of technical expertise.

Fast forwarding to the 1970s, James Watson described the cell’s inability to replicate up to
the tip of the chromosome as the “end replication problem” (Watson, 1972). By combining the
knowledge that the properties of DNA polymerase prevent cells from fully replicating the ends
of linear chromosomes with the observation that normal cells have a limited capacity to replicate,
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Olovnikov, was the first to suggest that chromosomal shortening may be linked to a cell’s
eventual mortality (Olovnikov, 1973). It has been reported that Olovnikov developed this
hypothesis while waiting for a subway train in Moscow. As he heard the train coming, he
imagined the train, and specifically the engine, being the DNA polymerase and the track being
the DNA. The engine (DNA polymerase) would not be able to replicate the first segment of
DNA (the track) because it lays exactly underneath the engine. It seemed unlikely that with each
cell division a DNA segment containing important genes was lost. Therefore, Olovnikov
reasoned that the repeated non-coding telomeric nucleotide sequences act as a buffer to protect
gene coding sequences. He correctly speculated that with each round of cell division a portion of
the telomere “buffer” would be lost, and that the length of the telomeric “buffer” could be
important for determining a cell’s ability to proliferate (reviewed in Hayflick, 1998; Greider,
1998).

In 2009 the Nobel Prize in Medicine or Physiology was jointly awarded to Elizabeth
Blackburn, Carol Greider and Jack Szostak for elucidating the structure and maintenance of
telomeres. The work leading to this prize dates back to 1978 when Blackburn, together with her
mentor Joseph Gal discovered the telomere’s DNA sequence (Blackburn & Gall, 1978). In
collaboration with Jack Szostak, Blackburn published evidence for the evolutionary conservation
of telomeres and their role in providing chromosomal stability (Szostak & Blackburn, 1982).
Furthermore, insight to the regulation of telomere length was gained by Greider and Blackburn
in 1983 by discovering enzymatic activity in Tetrahynema cell extracts that compensated the
incomplete replication in telomere ends (Greider & Blackburn, 1985). They subsequently
purified the enzyme and found it to be a ribonucleoprotein (RNP) that was comprised of an RNA
component, as well as a protein component. Thus, they had discovered a new type of DNA
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polymerase, which they named “telomerase” (Greider & Blackburn, 1987). Moreover, they
discovered that the RNA component contained the template required for the addition of
nucleotide repeats onto telomeres. Although all of these findings were in Tetrahymena, it is now
known that telomerase provides the main mechanism by which telomeres are elongated in
eukaryotes. Taken together, these discoveries were the foundation for the importance of telomere
biology in normal aging and in pathology.

Structure of the Telomeric Region
As a result of intensive research that has been completed since these pioneering studies,
much is now known about the telomeres. In humans, telomeres are stretches of non-coding
tandemly repeated “TTAGGG” DNA sequences that can reach a length of 15,000 base pairs.
They are located at the terminal ends of all vertebrate chromosomes, including those of humans
(Moyzis et al., 1988). Approximately 50-300 base pairs of single stranded DNA that is G-rich
extends from the 3’ strand forming an overhang that is thought to be important for telomere
function (Makarov et al., 1997, Wright et al., 1997). This single stranded 3’ overhang folds back
on itself forming a large loop structure called a telomere loop or T-loop, that has a shape similar
to that of a paper clip, and invades an upstream telomeric double stranded DNA forming a
displacement loop or D-loop.

Telomere stabilization and maintenance relies on a six-protein complex called shelterin,
which is composed of telomeric repeat binding factor 1 and 2 (TRF1 and TRF2), the human
ortholog of the yeast repressor/activator protein 1 (Rap1), TRF1 interacting nuclear factor 2
(TIN2), protection of telomerase 1 (POT1) and TPP1. Shelterin components specifically localize
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to the telomere due to the recognition of the duplex part by TRF1 and TRF2 and their interacting
proteins Rap1 and TIN2, whereas POT1 forms a heterodimer with TPP1 and recognizes the Gstrand overhang. These protein-DNA and protein-protein interactions are responsible for
maintaining telomere homeostasis (Palm & de Lange, 2008).

The chromatin structure of mammalian telomeres has properties that are characteristic of
heterochromatin. In particular, trimethylation of histone H3 lysine 9 (H3K9) and histone H4
lysine 20 (H4K20) are observed in telomeric and sub-telomeric regions (reviewed in Blasco,
2007). In addition, these regions are enriched in heterochromatin protein 1 (HP1), which is
important for chromatin compaction (reviewed in Blasco, 2007). Another mark of
heterochromatin that is present in telomeric and sub-telomeric regions is low levels of acetylated
H3 (AcH3) and H4 (AcH4) (reviewed in Blasco, 2007). Also, akin to heterochromatic regions,
the sub-telomeric regions are gene-poor, and the telomeric regions do not contain any genes
(reviewed in Blasco, 2007).

Telomere Functions
The telomere serves to cap chromosome ends and maintain genomic stability through various
mechanisms. One function is to prevent chromosomal ends from being distinguished as DNA
double strand breaks; thereby avoiding the activation of DNA damage signaling pathways and
genome instability (de Lange, 2009). Ataxia telangiectasia mutated (ATM) kinase pathway and
ataxia telangiectasia and Rad3 related (ATR) kinase pathway are activated in mammalian cells in
response to DNA double and single strand breaks in order to arrest the cell cycle and/or induce
apoptosis (programmed cell death). Moreover, homology directed repair (HDR) and non	
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homologous end joining (NHEJ) repair pathways can also be activated to ensure that cells
continue dividing with an intact genome. Telomeres, along with the shelterin complex, offsets
the effect of these four “repair” processes. Specifically, the TRF2 subunit of shelterin is
responsible for ensuring that the ATM kinase signaling pathway and NHEJ repair pathway are
not activated by formation of the T-loop. The POT1 subunit is responsible for repressing the
ATR kinase signaling pathway by preventing RPA, the single stranded DNA binding protein,
from binding to the telomeric single stranded DNA. Both TRF2 and POT1 block the activation
of the HDR pathway. Failure to do so causes cell cycle arrest under the direction of: a) ATM
and/or ATR; b) chromosome end-to-end fusion mediated by NHEJ; or c) sequence exchange by
HDR involving two telomeres or a telomere and another part of the genome (de Lange, 2002,
d’Adda di Fagagna et al., 2003, Bailey & Murnane, 2006).

Due to the inherent inability of the DNA machinery to fully replicate the end of linear
chromosomes, successive cell division leads to attrition of chromosome ends. Given that,
telomeres are capable of averting the end replication problem and avoiding the loss of valuable
genetic information by the presence of the cellular ribonucleoprotein enzyme telomerase, which
can add telomeric repeat sequences to the end of chromosomes (de Lange, 2009). Additionally,
telomere attrition can be compensated for through a recombination based telomeraseindependent mechanism termed alternative lengthening of telomeres (ALT) (Xu et al., 2013).

Regulation of Telomere Length
In humans, telomere length is maintained by the the enzyme telomerase, which is composed
of a reverse transcriptase protein (TERT) consisting of 1132 amino acids encoded by the hTERT
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gene, which is located on the short arm of chromosome 5 (5p15.33). Additionally, it is composed
of telomerase RNA component containing 451 nucleotides, which is encoded by the telomerase
RNA gene hTERC, which is located on the long arm of chromosome 3 (3q21-q28) (reviewed in
Aubert & Lansdorp, 2008). TERT uses the telomerase RNA component (that is complementary
to the telomere sequence) as a template for telomere repeat synthesis at the 3’ overhang.
Although telomerase is expressed during development, post-neonatal somatic cells repress
telomerase expression except in germ cells, stem cells and a subset of somatic cells (such as
active fibroblasts). Most neoplastic cells derepress the expression of hTERT to allow for
immortalization and tumor formation (reviewed in Cesare & Reddel, 2008).

As stated above, elongation of telomeres in cells not depending on telomerase is called ALT.
To date, most of the molecular details in ALT pathways remain unknown and very little is
known regarding the mechanism(s) by which this pathway is activated. Current findings suggest
that this process relies on homologous recombination between individual telomeres, where one
telomere serves as a template for recombination-based elongation of another telomere (Gocha et
al., 2013).

Telomere Shortening, Aging, and Disease
A lack of telomerase activity in the majority of normal cells is associated with the end
replication problem resulting in the loss of 50-100 base pairs at the telomeric end after each
round of cell division (Oeseburg & de Boer, 2010). This mechanism functions as a biological
clock to eliminate cells that have lived too long or long enough to accumulate aberrations and
mutations. Following approximately 50-70 cell doublings, gradual telomere shortening
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eventually results in critically short telomeres, leading to the activation of a DNA damage
response (DDR) and the cell enters a state of permanent growth arrest (senescence) or apoptosis
(Oeseburg & de Boer, 2010).

In humans, twin studies have concluded that telomere length is highly heritable, with
inheritance estimates ranging from 40% up to 80% (Slagboom et al., 1994, Vasa-Nicotera et al.,
2005, Andrew et al., 2006, Najajou et al., 2007). While genetic determination of telomere length
was thought to be X-linked, current evidence suggests paternal inheritance (Nawrot et al., 2004,
Nordfjall et al., 2005). At birth, one study found no difference in telomere length between sexes
in newborn (Okuda et al., 2002). Another study found that female newborns have longer
telomere lengths than males (Aubert et al., 2012). Moreover, adult males have been found to
have shorter telomere lengths than adult females suggesting an influence of environmental
factors and/or estrogen (Okuda et al., 2002, Hunt et al., 2008). Racial differences have also been
found to impact telomere length. In newborns as well as in adults, African-Americans have been
reported to have longer telomeres than Caucasians (Zanni & Wick, 2011, Drury et al., 2015).

Telomere attrition is one of the well-known cell intrinsic events associated with normal
cellular aging, both directly and indirectly. Cellular senescence is defined as a state where the
cell is unable to proliferate even with the availability of nutrients and mitogens (Campisi &
d’Adda di Fagagna, 2007). Given that aging is characterized by an increase in senescent cells in
many tissues and the observation of an inverse relationship between age and telomere length,
replicative senescence induced directly through telomere shortening is involved in the aging
process by limiting tissue renewal and influencing tissue homeostasis (Shay & Wright, 2005).
Although the physiological role of senescent cells is still poorly understood, these cells secrete
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pro-inflammatory cytokines, thereby negatively affecting the tissue microenvironment and
function (Collado, Blasco & Serrano, 2007).

In addition, oxidative stress has been implicated in triggering cellular senescence. Harman’s
“free radical theory” is one of the oldest of current theories suggesting that damage to cellular
macromolecules via free radicals is a major determinant of life span. Oxidative stress can be
defined as the net result of an imbalance between production and destruction of reactive oxygen
species (ROS) (reviewed in Kregel and Zhang, 2007). Because of it’s high content of guanine
bases, telomeric DNA is chemically more prone to oxidative damage, which, in turn, accelerates
telomere shortening (reviewed in Blackburn, Epil & Lin, 2015). Therefore, the notion of
telomeres acting as a cumulative measure of oxidative stress suggests an indirect involvement of
accelerated telomere attrition with normal cellular aging.

More importantly, telomere attrition and dysfunction have been shown to be a causal
factor in the acquisition of age-related diseases, including but not limited to atherosclerosis
(Bentos et al., 2004, de Beer et al., 2015); myocardial infarction (Brouilette et al., 2003, D’Mello
et al., 2016); Alzheimer’s dementia (Panossian et al., 2003, Guan et al., 2013); and heart failure
(reviewed in Oeseburg., 2010). Accelerated telomere shortening has also been associated with a
wide array of lifestyle factors such as smoking, consumption of unhealthy diet, obesity and lack
of exercise (reviewed in Shammas, 2011). Furthermore, telomeres are implicated in cancer
biology, due to their stabilizing effect on the chromosome and association with cellular
proliferation (de Lange, 2005, Xu et al., 2013). The progression from a normal cell to a cancer
cell occurs through a number of effects in which the cell acquires the so-called “hallmarks of
cancer” (Hanahan & Weinberg, 2000). Replicative telomere attrition is considered one of several
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regulatory mechanisms that blocks cell immortality, which is considered as one of the hallmarks
of cancer cells (reviewed in Xu et al., 2013). Replicative senescence occurs in a cell following
the activation of ATM and ATR signaling pathways and the associated downstream factors
including CHK1, CHK2, and phosphorylation of p53 and results in a cell cycle arrest in Gap 1
(G1) phase of the cell cycle, thereby inhibiting tumorigenesis (reviewed in Raynaud et al., 2008).
However, a DNA damage checkpoint deficient cell can continue dividing through p53 or pRb
inactivation, resulting in extensive telomere attrition. As a result, telomeres lose their protective
function, thereby allowing frequent chromosomal fusions and rearrangements, which, in turn,
leads to massive genomic instability, the latter of which can promote carcinogenesis. In addition,
cell death is bypassed and immortality is achieved by telomere length maintenance through the
up-regulation of telomerase in > 85% of human tumors (Raynaud et al., 2008). In the remaining
~15% of human tumors, telomere length is maintained by ALT (reviewed in Cesare & Reddel,
2008).

Impact of Environmental Factors on Telomere Length
Variation in the rate of biological aging reflects the accumulative burden of genetic,
metabolic and environmental stressors, resulting in oxidative damage and elevated inflammatory
processes (Lamb and Shiels, 2009). Stress results in the activation of the hypothalamic pituitary
adrenal (HPA) axis and the release of glucocorticoid hormones by the adrenal glands. These
hormones have been associated with reduced antioxidant capacity that may therefore cause
increased oxidative damage to the DNA and accelerate telomere shortening (Patel et al., 2002,
von Zglinicki, 2002, Irie at al., 2003). Telomere length have also been linked with various
psychological conditions (Lindqvist et al., 2015). Shorter telomere length has also been linked
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with longer duration of chronic stress (mothers caring for chronically ill children) in comparison
to mothers caring for healthy children with a difference equivalent to 10 years of life between the
two groups (Epel et al., 2004). Based on this observation, it could be hypothesized that women
under stress were at an increased risk of developing age-related health problems. In a similar
study, investigators reported higher depressive symptoms and shorter telomere lengths among
caregivers of patients with Alzheimer disease compared to gender and age-matched controls
(Damjanovic et al., 2007).

Beside psychological conditions, lifestyle behaviors have also been shown to impact
telomere length. Smoking is associated with accelerated telomere attrition through the increase in
oxidative stress with a pack of cigarettes a day for a period of 40 years being equivalent to 7.4
years of life (Valdes et al., 2005, Song et al., 2010, Babizhayev et al., 2011). Obesity also has a
negative impact on telomere length through obesity-related oxidative damage and the
deregulated production of adipocytokines (Valdes et al., 2005, Song et al., 2010). Exposure to
genotoxic agents that cause damage to the DNA and its association with telomere length have
also been evaluated. Chemotherapeutic drugs have been shown to have a negative impact on
telomere length by means of oxidative stress and uncapping telomeres (Lu et al., 2013, Liu,
Hales and Robaire, 2014). Radiation-induced telomere dysfunction has also been reported by
causing DNA double strand breaks, which are inefficiently repaired at the telomere or by
telomere uncapping in human cancers (Li et al., 2012, Mirjolet et al., 2015). However, the effect
of radiation on telomere dynamics has not been thoroughly studied. Investigators showed shorter
telomere length in traffic police officers exposed to toluene and benzene pollution, relative to
telomere length in office police workers (Hoxha et al., 2009). Similarly, significantly increased
chromosomal instability and shorter telomere length have been noted in coke-oven workers
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exposed to polycyclic aromatic hydrocarbons, relative to matched controls (Pavanello et al.,
2010). Furthermore, lower socio-economic status is associated with a decline in telomere length.
It is assumed that low income increases the likelihood of being on a poor quality diet, fat and
sugar rich, which are known to result in the production of more ROS(s) that directly causes DNA
breaks (Saretzki & VonZglinicki, 2002, Sheils et al., 2011). Also, the results of several studies
support associations of short sleep duration and poor quality sleep with shorter leukocyte
telomere length (Prather et al., 2015, reviewed in Tempaku, Mazzotti & Tufik, 2015).

In contrast, healthy lifestyle behaviors that decrease oxidative stress and inflammation have
been shown to preserve telomere length and reduce the pace of aging. Telomere length correlates
positively with the increased dietary intake of fiber (Cassidy et al., 2010). Moreover, a diet rich
in antioxidants, particularly, omega 3 fatty-acids is associated with reduced rate of telomere
shortening in participants of a study over a period of 5 years (Farzaneh-Far et al., 2010). In
addition, longer periods of physical activity and intensive sports have been associated with
longer leukocyte telomere lengths especially among older adults (Sabenroth et al., 2015, SoaresMiranda et al., 2015). A study in 2,401 healthy twins has shown that physically active
participants have longer leukocyte telomere length when compared with their age and gendermatched non-exercisers (Cherkas et al., 2008). Psychosocial stress reduction through
mindfulness meditation was not only found to increase telomerase activity in peripheral blood
mononuclear cells but also lengthen telomeres (Schutte & Malouff, 2014, Carlson et al., 2015).
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Telomere Length Measuring Techniques
There is a large and rapidly growing body of data showing the implication of telomere
biology in aging and disease processes. Indeed, telomere lengths have emerged as a potential
biomarker for risk assessment of diverse health outcomes (Fossel, 2012). The “gold standard”
method for measuring telomere length is the terminal restriction fragment (TRF) technique by
southern blot (Southern, 1979). Genomic DNA is typically digested using a cocktail of 4-6
restriction enzymes that lack recognition sites in telomeric and subtelomeric regions. The intact
telomere fragments are then visualized and size estimated via gel electrophoresis. In addition to
providing only an average of total telomere lengths, shortcomings of this assay include the need
for large amounts of DNA (micrograms), as well as the technique being labor intensive. Also,
inclusion of subtelomeric regions in this assay, due to the nature of the restriction enzymes used,
can provide an overestimation of the true telomere length (reviewed in Montpetit et al., 2014).

Polymerase Chain Reaction (PCR)-based techniques have also been used in measuring
telomere length by amplifying both telomere repeats and a single copy housekeeping gene(s)
(Cawthon, 2002, Cawthon, 2009). Calculating the ratio between the two quantities yields a
measure of relative telomere length (Cawthon, 2002, Cawthon, 2009). PCR-based methods
include quantitative PCR (qPCR), monochrome multiplex qPCR (MMqPCR), and absolute
telomere length (aTL) qPCR. Unlike the TRF assay, PCR- based telomere measuring assays
require small amounts of DNA (nanograms) and are considered high-throughput assays of
relatively low cost. However, like TRF, PCR-based methodologies do not provide information
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on telomere length at individual chromosome ends; hence they do not allow for the recognition
of specific chromosomes with short and/or dysfunctional telomeres (reviewed in Vera & Blasco,
2012).

Single telomere length analysis (STELA) is a telomere measuring assay that overcomes the
limitations of TRF and qPCR based methods by providing a length for specific individual
chromosomes (Baird et al., 2003). STELA is a qPCR-based technique that is designed to amplify
the telomeric DNA of a single chromosome, using primers that are specific for the sub-telomeric
sequence of that chromosome. Measuring telomere lengths on individual chromosomes is of
great importance since a single or a small number of short telomere(s) has (have) been suggested
to initiate a DNA damage response leading to senescence or apoptosis (Hemann et al., 2001,
Abdallah et al., 2009). Unfortunately, to date, telomeres of only a subset of chromosomes (Xp,
Yp, 2p, 11q, 12q, and 17p) can be measured through this technique due to the lack in specificity
of sub-telomeric regions between chromosomes. Another major disadvantage of this technique is
its limited ability for the analysis of very long telomeres (reviewed in Montpetit et al., 2014).

One of the most accurate telomere measuring methods is the Quantitative Fluorescence In
Situ Hybridization (Q-FISH) based assay (Lansdorp et al., 1996). Q-FISH of telomeric repeats is
assessed following hybridization with a fluorescent (CCCTAA) probe, with the remaining
3

chromatin on the chromosome being visualized by a nonspecific DNA stain such as DAPI or
propidium iodide (Krejci & Koch, 1998). Peptide Nucleic Acid (PNA) probes used in this assay
have higher hybridization efficiency to telomeric repeats than DNA probes because of their
neutral (uncharged) backbone (Egholm et al., 1993). Furthermore, PNA probes show increased
thermal stability of the probe-target duplex. Despite being labor intensive and expensive, this
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high resolution technique allows the quantification of each of the individual 92 human telomeres.
It is also powerful in detecting chromosomes with telomere free ends (< 0.5 kb) (reviewed in
Aubert, Hills & Lansdorp, 2012).
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Chapter 2
Introduction
Telomeres, which are crucial in maintaining genomic integrity and preventing chromosomal
instability have been suggested to play a role in carcinogenesis (Artandi & DePinho, 2010).
Among the different types of cancer, several studies have been conducted to investigate the
association between telomere length and breast cancer risk (Table 1; reviewed in Zhu et al.,
2016). Breast cancer (BC) is a very heterogeneous disease, both genetically and clinically, that
forms in tissues of the breast (Stingl & Caldas, 2007). A classification system has been
developed in order to standardize the disease and provide insight for better treatment and
prognosis strategies. Histologically, BC is categorized into in situ carcinoma and invasive
carcinoma (Malhotra et al., 2010). The two main subtypes of breast carcinoma in situ are ductal
carcinoma in situ (DCIS) (forms in tubes that carry milk to the nipple) and lobular carcinoma in
situ (LCIS) (forms in glands that produce milk) (Malhotra et al., 2010). Invasive breast
carcinoma forms in the ducts or lobules and spreads to other tissues of the breast, and is also
further subdivided into invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC).
Immunohistochemistry/FISH tests have been used to provide a molecular characterization of BC.
Key prognostic categories that have emerged are based on the expression status of the estrogen
(ER) receptors, progesterone (PR) receptors and/or human epidermal growth factor receptor-2
(HER2) status (Westbrook & Stearns, 2013). Estrogen receptor (ER) positive cancer refers to BC
in which the cells have an increased sensitivity to estrogen leading to cancer tumor growth.
HER2 positive breast cancer has an amplification (too many copies) of the HER2 gene and/or
increased expression of the HER2 protein, which causes the tumor to grow faster and the cancer
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to be more aggressive. Microarray-based gene expression analyses have further identified
molecular subtypes of BC as: basal like (ER-, PR-, and HER2-; also described as triple negative),
luminal subtype A (ER+ and/or PR+; HER2-, + or - Ki-67), luminal subtype B (ER+ and/or
PR+; HER2+, + or - Ki-67), and HER2 enriched (ER-, PR- and HER2+) (Perou et al., 2000,
Sorlie et al., 2001, Sorlie et al., 2003). In addition to the prognostic value of histopathological
classifications of BC, the identification of molecular subtypes enabled the prediction of response
to newer targeted therapies.

Clinical and histopathological factors, including tumor stage, tumor size and nodal status,
along with the growing knowledge of molecular biomarkers, have advanced the process of
choosing effective and safe treatment options for women with BC. Surgical courses of action in
operable tumors include breast-conserving surgery (also called lumpectomy) for early-stage BC
or mastectomy for advanced BC (Myers, 2016). Neoadjuvant approaches (chemotherapy and
hormonal therapy prior to surgery) for selected high-risk BC aims at shrinking the tumor size to
potentially reducing the extent of surgery (Thompson & Moulder-Thompson, 2012). Adjuvant
systemic therapy is a standard of care after surgery to eradicate possible micrometastatic tumor
and lower recurrence risk in early-stage disease through the use of chemotherapy and hormonal
therapy, whereas in advanced stage BC, it serves to control disease burden and improve survival
(Myers, 2016). In the case of ER positive BC, which accounts for approximately 80% of BC,
hormonal therapy is the initial treatment of choice in the form of selective estrogen receptor
modulators (SERMs) such as tamoxifen and raloxifene or aromatase inhibitors (AIs) (Westbrook
& Stearns, 2013). HER2 targeted therapies include trastuzumab, pertuzumab, ado-trastuzumab
emtansine, and lapatinib. Trastuzumab, which is the most commonly used therapeutic agent for
women with HER2+ tumors, uses a monoclonal antibody that binds to the HER2 receptor,
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thereby suppressing cell proliferation (Giordano, Tagliabue & Pupa, 2012). Triple negative
breast cancer is considered aggressive, with no targeted therapy available. Therefore, cytotoxic
chemotherapy is an option offered for patients with this type of BC (Myers, 2016). There are
several classes of cytotoxic chemotherapeutic agents, including anti-metabolites, antimicrotubules, anthracyclines and cychlophosphamide (Westbrook & Stearns, 2013). One
example of an anti-metabolite is capecitabine, which slows tumor growth by inhibiting DNA
synthesis during the S phase of the cell cycle within the tumor (Parker, 2010). Among the most
effective of the antimicrotubules treatments are the taxanes paclitaxel (taxol) and docetaxel
(taxotere) (Westbrook & Stearns, 2013). These drugs inhibit microtubule formation, leading to
mitotic arrest and suppression of cell growth (Fauzee, 2011). The anthracyclines doxorubicin
(adriamycin) and epirubicin have been extensively used in the course of treatment for BC (Quiles
et al., 2002). Several mechanisms have been proposed for doxorubicin-mediated cell death,
including topoisomerase II poisoning, DNA adduct formation, oxidative stress and ceramide
overproduction (Gewirtz, 1999, Minotti et al., 2004, Senchenkov, Litvak & Cabot, 2001, Yang et
al., 2014).

Cancer is a leading cause of death in both more and less economically developed countries.
In 2013, there were 14.9 million incident cancer cases worldwide. Of these, BC was the leading
cause for cancer incidence among women, accounting for 1.8 million of those cases (Global
Burden of Disease Cancer Collaboration, 2015). In 2016, approximately 246,660 women are
expected to be diagnosed with BC and 40,450 deaths from BC are estimated in the United States
(Siegel, Miller & Jemal, 2016). However, since the year 2000, BC mortality rates decreased
significantly due to the availability of better screening tools, advanced detection strategies, and
continually improving treatment options (Jemal et al., 2013). Although these factors have
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increased the survival rate to at least five years in 90% of women receiving an early diagnosis,
many cancer survivors have reported the occurrence of a number of distressing symptoms
leading to long term effects that adversely affect their quality of life (QOL) (Jemal et al., 2009,
Dodd et al., 2010). These symptoms, which manifest from the cancer itself or it’s treatment
include (but are not limited to): anxiety, fatigue, depression, pain, stress, and sleep disturbances,
which we are collectively categorizing as “psychoneurological symptoms” (PNS) (Lee at al.,
2004, Badger et al., 2007, Bardwell & Ancoli-Israel, 2008, Bower, 2008, Weinberger et al.,
2010, Satija et al., 2014, Jung et al., 2016). PNS not only impact treatment decisions in patients
with BC but can also challenge the cancer survivor’s ability to perform and maintain
employment, connect with loved ones and carrying on day-to-day tasks (Hurria, Somlo & Ahles,
2007). Although there is increased awareness to the importance of understanding the biological
basis of PNS, the molecular mechanism(s) leading to the development and persistence of PNS
remains inconclusive.

One reason patients may present with a number of symptoms, rather than a single symptom,
is that these symptom “clusters” may share a common biological mechanism (Miaskowski &
Aouizerat, 2007). Several studies have been conducted in order to understand the biological
mechanism(s) underlying the development of PNS. Symptoms of cancer/cancer treatment are
thought to be due, at least in part, to cytokine-induced sickness behavior (Cleeland et al., 2003).
Cytokines are present in increased levels in patients with cancer (Meyers et al., 2005) and can be
produced from tumor tissues (Sasaki et al., 2001) or in both tumor tissues and healthy cells in
response to chemotherapy (Pusztai et al., 2004). Although cytokine-induced sickness behavior is
considered a reasonable mechanism leading to symptom clustering in patients with cancer, it can
not account for all the clusters reported to date; the reason being that several investigators have
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reported different numbers of symptoms in a cluster, as well as different types of symptoms
within a cluster (Miaskowski and Aouizerat, 2003). Several investigators have shown an
association between each of the PNS and the activation of inflammation markers, particularly
pro-inflammatory cytokines (reviewed in Kim et al., 2012). However, these studies have been
limited because they focused on single symptoms and single markers of inflammation, and they
haven’t clearly explained the mechanism leading to the development and persistence of PNS. A
higher than expected incidence of some PNS as well as pro-inflammatory cytokines, have been
reported prior to the initiation of chemotherapy (Meyers et al., 2005). This suggests that
inflammation may be activated by the cancer itself, with the symptoms being worsened by
chemotherapy. In addition, it has been suggested that some of these PNS, such as depression and
fatigue, are actually caused by perturbations in cytokine levels acting on the brain (Dantzer et al.,
2008). However, the fact that inflammatory molecules, such as cytokines, are not retained for
long periods of time, and the fact that these symptoms have been reported to persist in a subset of
cancer survivors for years after therapy, led us to hypothesize that inflammation is an initiating
step for a cascade of biological events that also include the acquisition of somatic cell genetic
(e.g. telomere length changes; chromosomal instability) and/or epigenetic changes (e. g.
methylation alterations), with these latter genetic/epigenetic alterations providing a means for the
effects of the BC and/or its treatments to be maintained in one’s biological memory.

Acquired telomere attrition has long been speculated as a causal factor in the acquisition of
many chronic diseases (Blackburn, Epil and Lin, 2015). Furthermore, accelerated telomere
shortening has been shown to play a role in the pathogenesis of multiple psychological
conditions such as, but not limited to, stress, depression and cognitive decline, all of which are
major side effects experienced by patients with BC (reviewed in Starkweather et al., 2014).
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Telomere shortening can be accelerated by multiple factors associated with the cancer itself or
it’s treatment including (but not limited to) chemotherapy and oxidative damage (von Zglinicki,
2002, Li et al., 2012). Interestingly, increased inflammatory activity can accelerate telomere
attrition by inducing cell turnover and replicative senescence or by the release of ROSs that
shorten and damage telomeres through oxidative stress (Aviv, 2004, Jaiswal et al., 2000).
Induced cellular proliferation/senescence could contribute to PNS, at least in part, through
compromised tissue homeostasis. In addition, shortening of telomeres has been associated with
an increased frequency of chromosomal instability, which, in turn, could give rise to alterations
in gene expression, thereby allowing the persistence of PNS. Furthermore, a reduction in the
telomere heterochromatic region as a result of telomere attrition could alter gene expression of
adjacent subtelomeric genes through a phenomenon known as “telomere position effect” (TPF)
(van Deutekom et al., 1996, Baur et al., 2001, Robin et al., 2014). One can speculate that an
epigenetic alteration in the genes juxtaposed to the telomeric region, could provide a plausible
mechanism for the persistence of PNS into survivorship.

As noted earlier, telomere length alterations in patients with BC have been evaluated
extensively as a diagnostic marker in breast tissues, but few investigators have incorporated the
effect of chemotherapy on the telomere lengths of healthy, peripheral tissues in these patients
(Meeker et al., 2004). However, research involving measuring telomere length in peripheral
blood lymphocytes has been completed, with a focus on investigating the potential link between
telomere length and the risk for developing BC or other age-related diseases (Table 1) (Heaphy
& Meeker, 2011, Barrett et al., 2015). The results of one study on leukocytes obtained from
patients with early stage BC showed decreased telomere length at five and nine months
following chemotherapy when compared to baseline values (Schroder et al., 2001). However,
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information regarding PNS was not integrated into that study since the main focus was to
determine the effect of stem cell transplantation following chemotherapy in the evaluated group
of patients.

Given that telomere shortening is accelerated by inflammation and oxidative stress, and that
chemotherapy affects both of these processes, the primary objective of this study was to
longitudinally evaluate telomere length in women diagnosed with early stage BC who were
treated with chemotherapy in order to determine if chemotherapy contributes to chromatin
breakage within the telomere, thereby leading to telomere shortening in this group of
patients. Results from this study will allow us to test the following hypotheses:
1.   There is a change in telomere lengths following treatment with chemotherapy in women
diagnosed with early stage BC.
2.   These differences in telomere lengths affect a subset of chromosomal arms rather than
affecting all chromosomes equally.
3.   The extent of change in telomere length differs based on the type of chemotherapy regimen
used for treatment.
4.   A correlation exists between telomere length changes following treatment for BC and a
survivor’s acquisition of PNS.

To our knowledge, this is the first longitudinal study that provides information about
telomere lengths over five time points, including pre-, during and post-chemotherapy treatment.
Moreover, it is the first study to provide information about chromosome-specific telomere length
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changes associated with chemotherapy. These expanded observations are expected to provide
new insights in the use of peripheral blood telomere length as a biomarker for the identification
of individuals who are sensitive to a specific type of chemotherapy and/or at higher risk for the
development of PNS.
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Table 1: Studies on the Association Between Telomere Length and Risk for BC

Reference

Year

No. of
Case/Control

Sample
source

Method

Study outcome

Barewell et
al.

2007

72/1696

Leukocyte

TRF

TRF derived telomere
length is not a marker for
BC susceptibility

Shen et al.

2007

283/347

Leukocyte

qPCR

Modest evidence that short
telomere length is
associated with increased
breast cancer risk

Shen et al.

2009

1026/1070

Leukocytes

qPCR

Short telomere length is
associated with breast
cancer risk in premenopausal women and
women with low
antioxidant dietary or
supplementary intake

De Vivo et
al.

2009

896/917

Leukocytes

qPCR

No significant association
between postmenopausal
BC risk and short telomere
length

Zheng et al.

2010

293/335

Leukocytes

Q-FISH

Increased risk of BC with
shorter telomere length on
chromosome 9p, 15p, 15q
and Xp

Gramatges et 2010
al.

102/50

Leukocytes

qPCR

Longer telomere length in
women at high risk for BC
based on family history

Kim et al.

2011

342/735

Leukocytes

qPCR

No association between
telomere length and BC risk

Qu et al.

2013

601/695

Leukocytes

qPCR

Shortened telomeres is
associated with increased
risk of BC

Pellatt et al.

2013

728/720

Leukocytes

qPCR

Longer telomere length is
associated with increased
BC risk

Adapted from reviewed in Zhu et al., 2016.
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Chapter 3
Materials and Methods

Study Participants Ascertainment
A total of 77 women with early stage (I to IIIA) breast cancer were ascertained through
the Massey Cancer Center (MCC) in Virginia Commonwealth University and its multiple
collaborative sites, including Hematology Oncology Associates of Fredericksburg, Inc., Bon
Secours Richmond Health System, Peninsula Cancer Institute, and Rappahannock General
Hospital. To identify potential study participants, a member of the research team attended the
weekly interdisciplinary Breast Health meetings at Virginia Commonwealth University Health
System (VCUHS). The eligibility criteria were: 1) an age of 21 years or older; 2) a diagnosis of
early stage BC with a scheduled visit to receive chemotherapy; and 3) a female gender.
Exclusion criteria were a history of: 1) a previous cancer, or chemotherapy; 2) a diagnosis of
dementia; 3) active psychosis; or 4) immune-related diagnosis (e.g. multiple sclerosis; systemic
lupus erythematous). From the list of patients presented at the meeting, those persons meeting
the study inclusion criteria were identified. The study coordinator then consulted with the
attending oncologist and with his/her approval approached the patient regarding her desires to
participate in the study. The offsite research nurses followed similar procedures for identifying
potential participants at his/her respective site.

After providing their informed consent (VCU IRB # HM 13194), all participants in this
longitudinal study completed questionnaires and cognitive testing via a computerized system at
each of the five time points, which were: 1) visit 1 (also referred to as “baseline”) which was
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prior to chemotherapy; 2) visit 2 (also referred to as “mid-chemo”), which was prior to the fourth
cycle of chemotherapy; 3) visit 3, which was scheduled approximately 6 months following the
initiation of chemotherapy, at which time a subset of women received radiotherapy; 4) visit 4,
which was scheduled approximately 1 year following the initiation of chemotherapy; and 5) visit
5, which was scheduled approximately 2 years following the initiation of chemotherapy. During
each visit, blood samples (in green top (sodium heparin) tubes and lavender (EDTA) tubes) were
collected by venipuncture or an existing access device and transported to the cytogenetics
laboratory in a biohazard container. The lab staff were blinded to the clinical history and therapy
status of the study participants at the time of sample processing and evaluation.

Demographic, Lifestyle and Clinical Health Information
Demographic and lifestyle information was obtained from each study participant via self
reporting questionnaires. The subset of the demographic data selected as most relevant for this
current study included age, race and income. Clinical health information was obtained from
medical records. This information included BC stage, BC grade, chemotherapy regimens and
tumor characteristics. Tumors were characterized based on FISH and/or immunohistochemical
testing results as luminal A (ER+ and/or PR+; HER2- ;no information was available on Ki-67),
luminal B (ER+ and/or PR+; HER2+; no information was available on Ki-67), HER2 positive
(ER-, PR- and HER2+) and triple negative (ER-, PR-, and HER2-) (Perou et al., 2000, Sorlie et
al., 2001, Sorlie et al., 2003).
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Treatment
Chemotherapy treatment for each study participant was administered as either: 1) Taxotere
(docetaxel), Adriamycin (doxorubicin), and Cyclophosphamide [TAC]; 2) Taxotere and
Cyclophosphamide [TC]; or 3) Taxotere (docetaxel), Carboplatin (paraplatin) and Herceptin
(transtuzumab) [TCH]. Information regarding chemotherapy and radiation therapy for each
patient was determined from medical records.

DNA Isolation
Genomic DNA was extracted from whole blood using a Puregene DNA Isolation Kit
(Qiagen) according to the manufacturers protocol. After extraction, the DNA was quantified,
evaluated to ensure it was not degraded, and stored at -80°C. DNA stocks were diluted to
approximately 20 ng into pure water prior to setting up qPCR runs.

Monochrome Multiplex qPCR (MMqPCR)
The relative genomic telomere length was measured by monochrome multiplex real-time
quantitative PCR (MMqPCR) as previously described, in which both the telomere and the
housekeeping gene values are derived from the same well (Cawthon, 2009). The primer
sequences used for this assay are shown in Table 2. In this method, relative telomere length is
determined as a ratio of the number of copies of the telomere repeat sequences compared to the
copies of a single housekeeping gene (human albumin), with this number being derived from a
standard curve. This 5-point standard curve was derived from triplicate measures on each assay
plate. DNA for the standard curve was made from a “cocktail” of 11 healthy control women and
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was prepared in dilutions ranging from 1.235 to 100 ng. PCR reactions were set up by aliquoting
5 µL of 4 ng experimental DNA followed by 15 µL of SYBR Green Mastermix combined with
telomere primer and albumin primer into each reaction well of a 96-well plate. Each plate was
set up to include “standard DNA” in triplicate; experimental DNA in triplicate; a triplicate of a
negative control (lacking DNA); and a triplicate of a positive control, which is DNA extracted
from HeLa cells (known to have high T/S ratio), a normal female control age 35 cells (known to
have medium T/S) ratio and MCF7 cells (known to have low T/S ratio). All 5 visits for each
study participant were run on the same plate. This assured that comparisons between the five
time points were always within the same batch, thus eliminating possible biases due to batch
differences. An additional layer of quality control was our use of one single lot for each reagent
for the entire study to eliminate possible batch differences due to different reagent lots.

Plates were run on a BioRad CFX96 with the following cycling parameters: 95oC for 5
minutes; 2 cycles of 94oC for 15 seconds, 49oC for 15 seconds; 49 cycles of 15 seconds at 94oC,
15 seconds at 62oC, 15 seconds at 83oC, 15 seconds at 60oC with signal acquisition, 15 seconds
at 94oC, 20 seconds at 85oC with signal acquisition. The 60oC reads provided the the Ct values
for the amplification of the telomere template (in early cycles when the albumin signal is still at
baseline). The 85oC reads provided the Ct values for the amplification of albumin template at
which time the telomere template is fully melted. BioRad CFX Manager software version 3.0
automatically estimated the value for each T (telomere) and S (albumin single copy gene) using
the standard curve.
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Table 2: Primer Sequences for MMQPCR

Site
Telomere

Primer Sequence
telg: ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT
telc: TGTTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAACA

Albumin

albu: CGGCGGCGGGCGGCGCGGGCTGGGCGGaaatgctgcacagaatccttg
albd: GCCCGGCCCGCCGCGCCCGTCCCGCCGgaaaagcatggtcgcctgtt
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Cell culture, Chromosome Harvest and Slide Preparation
Upon receiving the blood samples (in sodium heparin), leukocytes were isolated using
Histopaque- 1077 (Sigma). Duplicate stimulated (using phytohemaglutinin (PHA)] lymphocyte
cultures were established and harvested using standard procedures [RPMI 1640 media,
supplemented with 15% Fetal bovine serum (FBS)]. Twenty minutes prior to harvesting,
colcemid (final concentration of 0.1 µg/ml) was added in order to limit microtubule formation by
inactivating spindle fiber formation, which arrested the cells in metaphase. Seventy-two hours
after culture initiation, the cultures were harvested as previously described (Leach and Jackson
Cook, 2001) using standard protocol techniques, including a 20-minute incubation in hypotonic
solution (0.075 M KCl), a ten-minute incubation (room temperature) in fixative (3:1 methanol:
acetic acid solution) and two additional washes in fixative. In order to reduce cytoplasm
formation, which can compromise probe hybridization, slides were made using a Thermotron,
which provided a constant temperature (23°C) and humidity (48 ±1°C). A phase contrast/bright
field microscope was used to ensure that the quality of the slide preparation was optimal for the
FISH analysis (i.e. enough metaphases present that lacked cytoplasm, had good morphology, and
were well spread). The slides were then placed on a hot plate at 60°C for an hour, followed by
aging at room temperature for 1-2 weeks. Alternatively, following hot plate incubation, room
temperature aging was induced by soaking the slide in a 2xSSC solution for ten minutes prior to
applying the FISH protocol.
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Chromosome-Specific Telomere FISH
The telomere length of metaphase chromosomes was assessed using a telomere- specific
FITC-labeled peptide nucleic acid (PNA) probe, following the manufacturer’s protocol
(DakoCytomation, Denmark). Briefly, target slides were soaked in cold fixative (3:1 methanol:
acitic acid) for one hour. Following air-drying, the slides were rinsed in 1xTBS (Tris-Buffered
Saline, PH 7.5) for two minutes, fixed in 3.7% formaldehyde in 1xTBS for two minutes, and
then rinsed twice in 1xTBS (for five minutes each time). The slides were then immersed in a pretreatment solution containing proteinase K for ten minutes and rinsed twice in 1xTBS for five
minutes each. Following dehydration in an ethanol series (70%, 85% and 100%) for two minutes
each, the slides were air-dried. After drying, 22 µl of FITC labeled PNA probe (CCCTAA)3 was
added to each full slide and a coverslip added. Following the co-denaturation of the probe and
metaphase chromosomes in a thermocycler at 80°C for three minutes, the slides were hybridized
in a dry hybridization chamber at room temperature for two hours. Unbound and excess probe
was then removed by washing in a rinse solution (provided by the manufacturer) at room
temperature for two minutes, as well as a second wash solution (provided by the manufacture) at
65°C for five minutes. After washing, the slides were dehydrated in a series of cold ethanol
solutions (70%, 85% and 100%) for two minutes each. Finally, the slides were air-dried and
counterstained with 24 µl of a 5:1 DAPI II /propidium iodide (Abott) solution.  

Telomere Image Analysis
A total of ten metaphases for each individual were analyzed using software on an Applied
Imaging Cytovision system (the Comparative Genomic Hybridization (CGH) function) as
previously described (Leach et al., 2004). Briefly, for each metaphase analyzed, three images
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were captured using a CCD camera. The first image was captured using a DAPI filter to allow
for subsequent karyotyping and identification of the chromosomes based on their reverse DAPI
banding pattern. The second image was captured using a FITC filter, which allowed for the
visualization of the telomeric probe and is termed by the software as the “test image”. The third
image allowed for the visualization of the chromosomal body based on its propidium iodide stain
and is termed a “reference image”. Karyograms were prepared for each metaphase spread,
followed by the designation of the centromere and central axis for each homolog. For each
telomere, the software compared the fluorescence intensity from the “test image” to the
fluorescence intensity of the propidium iodide stain in the chromosomal body from the
“reference image” to generate a ratio profile for each chromosome. For each study participant the
intensity values were averaged over the twenty homologs from the ten metaphase spreads scored.
Overlapping chromosomes at the telomere region were omitted from the analysis. Representative
images are shown in Figure 1.
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Figure 1: Representative images of chromosome-specific telomere FISH. For each
individual, 10 metaphases are analyzed and for each metaphase 3 images are captured. (A)
Shows a metaphase spread stained with DAPI. (B) The metaphase as it appears with reverse
DAPI bands, allowing for chromosome recognition. (C) Shows a “test image” showing telomere
signals at the end of each chromosome arm, captured using a FITC filter. (D) Represents the
“reference image” showing the same metaphase with a propidium iodide stain. (E) A
representative chromosome 3 from one participant as it appears in DAPI, FITC labeled, merged
and PI image, respectively. Also, the ratio profile of this chromosome is shown. From this profile
(and the visual image) one can see that the short arm telomere (top of chromosome) has a larger
fluorescence intensity value (6.63) than the long arm telomere (bottom of chromosome) (value of
4.63).
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Assessment of PNS
The following symptoms were measured by our collaborators at Virginia Commonwealth
University School of Nursing according to the systems described:

•   Cognitive Dysfunction
The CNS Vital Signs computerized neurocognitive testing system was used to measure
cognitive dysfunction in our study participants (Gualtieri & Johnson, 2006). This system has
been highly recommended for the use in longitudinal studies due to its high sensitivity to mild
cognitive impairment. This system has the ability of excluding practice effects by randomly
generating alternate test forms. Repeated measures of cognitive components with a concentration
on memory and attention were achieved through a highly reliable and well-validated screening
system (Gualtieri & Johnson, 2006).

•   Stress
Percieved Stress Scale (PSS) is considered one of the widely used psychological
instruments due to its well-documented reliability and validity (Cohen, Kamarck &
Mermelstein, 1983). Participants rated how often they found their lives to be unpredictable,
uncontrollable, and overloaded during the past month through a 10 item Percieved Stress Scale
(PSS) (Cohen, Kamarck & Mermelstein, 1983). Each question has five possible Likert scale
responses (never, almost never, sometimes, fairly often, and very often). Of the total responses
on the PSS, 6 were “negative” responses and were given the following numerical value: never
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= 0; almost never = 1; sometimes = 2; fairly often = 3; and very often = 4. The remaining 4
positive items in the PSS were recorded in a reversed format according to standard approaches
(i.e. never = 4…very often = 0) (Innes et al., 2012, Abut et al., 2012). All 10 response values
were then summed to calculate the participants’ total perceived stress score, with higher scores
indicating higher levels of perceived stress (Cohen, Kamarck & Mermelstein, 1983).

•   Depression and Anxiety
The Hospital Anxiety and Depression Scale (HADS) was used to determine the presence and
severity of depression and anxiety (Snaith, 2003). It is a questionnaire-based test where the study
participant rated from 0-3 the severity of each symptom on 14 items over a period of 7 days. This
assessment tool was selected for use in this study because it has been shown to have an excellent
reliability and validity in patients with BC (Snaith, 2003).

•   Pain
Pain was assessed using the Brief Pain Inventory (BPI), which is a self-reporting short
form that is directed towards the assessment of pain severity and its impact on daily function in
patients with pain from chronic diseases or cancer (Caraceni, 2001). Validity and reliability
has been well established for these patients using this tool. Assessment areas include severity
of pain, impact of pain on daily function, location of pain, pain medications and amount of
pain relief in the past 24 hours or the past week. This test doesn’t require a scoring algorithm;
it relies on “worst pain” or the mean of the four severity items as a measure of pain severity,
and the arithmetic mean of the seven interference items as a measure of pain interference
(Caraceni, 2001).
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•   Fatigue
Fatigue was measured using the Brief Fatigue Inventory (BFI), which is a self-reporting test
that is designed for patients with fatigue due to cancer and its treatment (Mendoza et al., 1999).
This 9-item scale aids in the assessment of fatigue severity and the impact of fatigue on daily
functioning in the past 24 hours. A global fatigue score can be obtained by averaging all the
items on the BFI with severe fatigue being defined as a score of 7 or higher. This test has been
used in clinical trials and has shown excellent reliability (Mendoza et al., 1999).

•   Sleep Disturbances
The General Sleep Disturbance Scale (GSDS), as a means of obtaining self-reported sleep
issues including problems initiating sleep, the number of awakenings, excessive daytime
sleepiness and the use of medications to induce sleep over the past week (Lee, McEnany &
Weekes, 1999). The 21 items in this tool are rated using a numeric rating scale ranging from 0 to
7. The total score for this scale ranges from 0 (no sleep disturbance) to 147 (extreme sleep
disturbance) and is calculated by summing the 21 items (Lee, McEnany & Weekes, 1999).

Chromosome Instability Assessment
Chromosomal instability levels were quantified for each study participant using the
cytokinesis-block micronucleus (CBMN) and cytome assay as previously described (Aboalela et
al., 2015).
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Statistical Analyses
Demographics, tumor characteristics and treatment variables in Tables 2-4 were computed
using chi square tests for categorical data and a two sample t-test for continuous data when
looking for differences in race (African Americans vs. Caucasian). A Pearson correlation was
used to examine the correlation between age and telomere length, as well as between MN
frequency and telomere length. The percent change in telomere intensity values for each
chromosomal arm (p arm and q arm) from baseline to mid-chemo for each study participant was
determined by the following formula:
(Mid-chemo telomere intensity value - Baseline telomere intensity value) X 100
Baseline telomere intensity value
A paired t-test was used to compare mean telomere intensity values for each chromosomal arm
between baseline and mid-chemo.

Using the model building approach proposed by Hosmer and Lemeshow (2000), a mixed
effects linear model (Brown & Prescot, 2006) was fit to determine the best subset of predictors
of qPCR-based telomere length. In the first stage of the model building process, a base model
was selected that represented the design of data collection and the timing of treatments
(chemotherapy and radiation). Fixed effects included, visit (baseline, mid-chemo, six months
following the initiation of chemo, 12 months and 24 months post-chemo), chemotherapy
regimens, visit by chemotherapy interaction (chemotherapy was administered only during visit
2), radiation (Yes/No); visit by radiation interaction (radiation was only administered proximal to
visit 3), and a random effect for study participants. In the second stage, each potential predictor
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was fit individually with the base model and if the p-value was 0.25 or less, that predictor was
used in the third stage. Potential predictors tested included demographic variables (age, race, and
income), tumor characteristics (grade, stage, luminal A, luminal B, triple negative and HER2
positive status) and neoadjuvant status. In the third stage, all potential regressors (p	
  ≤ 0.25) were
put into a multiple variable model. This initial model was further refined by sequentially
removing variables from the model with the highest p-values (backward stepwise) until all
remaining factors had a p-value of 0.05 or less. This model was considered the final prediction
model. Least square means of significant predictor variables were tested using a Tukey test. To
identify significant predictors of chromosome-specific telomere length, the previous base model
was used with the exception of excluding radiation variable because chromosome-specific data
was produced from only baseline and mid-chemo time points. In addition, instead of using a
backward stepwise approach, each of the above mentioned potential predictors of chromosomespecific telomere length was fit individually and was considered a significant predictor when
having a p-value of 0.05 or less. JMP Pro 12 statistical package was used for the mixed effect
model and correlation analyses. R 3.2.0 software was used for the paired t-test.
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Chapter 4
Results
A total of 77 women with early stage breast cancer (I – IIIA) were recruited for this study.
One participant provided only a baseline specimen and then withdrew from the study citing a
“lack of time/interest” as the reason for her withdrawal. Two women failed to provide specimens
for all five time points and explained that they had a lack of time as their reason for noncompliance with the study protocol (96% retention rate). Only two women received
cyclophosphamide, methotrexate and 5 fluorouracil (CMF) treatment. Therefore, due to the small
sample size, this subset of participants was excluded from the analysis. Telomere length
assessment was completed for a total of 72 participants of the 77 originally enrolled in the study.
The majority of these study participants received TAC treatment (n= 39), followed by TC (n=
21), or TCH (n= 12).

Demographics
Demographics, breast tumor characterization and treatment information for the 72 women
participating in this longitudinal study are shown in Tables 3-5. One woman in the African
American cohort and one woman in the Caucasian cohort self-reported being of Hispanic or
Latino ethnicity. Given the small number of the Hispanic sub-group, these women were included
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in the African American and Caucasian sub-groups, respectively, but the Hispanic ethnic group
was not analyzed separately. The age of the women fully participating in the study ranged from
23 to 71 years, with a median of 52 years. A significant difference in age was observed between
the African American (n=22, mean = 46.6 years, standard error (s.e.) = 2.07 years) and
Caucasian (n = 50, mean = 53.5 years, s.e. = 1.37 years) sub-groups (p = 0.007) (Table 3).
Annual income also differed significantly between the two racial groups, with Caucasians having
higher income than African Americans (p < 0.0001) (Table 3).

Tumor Characteristics
In accordance with this study design, only women with early stage breast cancer (stages I –
IIIA) were included. There was no significant difference in the grade of the breast cancer tumors
present in the African American compared to Caucasian women (p = 0.197) (Table 4). Similarly,
no significant difference was observed for the stage of breast cancer between the two racial
groups (p = 0.055) (Table 4). While there was no significant difference in the proportion of
tumor sub-types, there was a trend toward a higher proportion of luminal A tumors and a lower
proportion of HER2+ and triple negative tumors in the Caucasian population (60% luminal A
tumors; 10% luminal B tumors; 6% HER2+; 24% triple negative tumors) compared to African
Americans (36 % luminal A; 9% luminal B tumors; 18% HER2+; 36% triple negative tumors)
(Table 4).

Treatment
The three main types of chemotherapy regimens administered to the study participants were
categorized as 1) TAC, which included sequential administration of doxorubicin (Adriamycin),
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cyclophosphamide (Cytoxan), and docetaxel (Taxotere); 2) TC, which included docetaxel
(Taxotere) and cyclophosphamide (Cytoxan); and 3) TCH, which included docetaxel (Taxotere),
Carboplatin (Paraplatin), and trastuzumab (Herceptin). No significant difference in
neoaduvant/adjuvant status (p = 0.123), chemotherapy regimens (p = 0.291) or radiation
treatment (p =0.229) was observed between the racial groups (Table 5).
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Table 3. Demographics for Study Participants Receiving Chemotherapy for Breast Cancer
African American
n= 22

TAC
n=10
(45%)

Caucasian
n= 50

TC
n=6
(27%)

TCH
n=6
(27%)

AA Total TAC
n= 22
n=29
(100%)
(58%)

44.0
3.4

47.0
2.5

50.5
2.9

52.2
1.7

Less than
30,000

5 (23%)

4 (18%)

3 (14%)

12 (55%)

6 (12%)

1 (2%)

0

7 (14%)

30,000 –
59,999

3 (14%)

2 (9%)

3 (14%)

8 (37%)

6 (12%)

1 (2%)

0

7 (14%)

60,000 –
89,999

1 (4%)

0

0

1 (4%)

6 (12%)

7 (14%)

3 (6%)

16 (32%)

90,000 +

1 (4%)

0

0

1 (4%)

11 (22%)

6 (12%)

3 (6%)

20 (40%)

Age

TC
n=15
(30%)

TCH
n=6
(12%)

57.1
2.6

C. Total
n= 50
(100%)

51.0
5.2

Income

•   Number in parentheses is the percentage of participants in this category (%)
•   For age, the mean (top line) and standard error (bottom line) are shown
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Table 4. Breast Tumor Characteristics in the Study Participants
African American
n= 22

Caucasian
n= 50

Luminal A
Yes

8 (36.3%)

30 (60%)

No

14 (63.7%)

20 (40%)

Yes

2 (9%)

5 (10%)

No

20 (91%)

45 (90%)

Yes

8 (36%)

12 (24%)

No

14 (64%)

38 (76%)

Yes

4 (18%)

3 (6%)

N

18 (82%)

47 (94%)

1

1 (4%)

4 (8%)

2

12 (55%)

16 (32%)

3

9 (41%)

30 (60%)

Luminal B

Triple negative

HER2 positive

Grade
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Stage
I

5 (22%)

15 (30%)

IIA

11 (50%)

19 (38%)

IIB

6 (28%)

8 (16%)

IIIA

0

8 (16%)

•   Number in parentheses is the percentage of participants in this category (%)
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Table 5: Treatment Characteristics in the Study Participants
African American
n= 22

Caucasian
n= 50

Neoadjuvant
Yes

4 (18%)

3 (6%)

No

18 (82%)

47 (94%)

Yes

6 (27.5%)

8 (16%)

No

16 (72.5 %)

42 (84%)

19 (87.5%)

37 (74%)

3 (12.5%)

13 (26%)

Herceptin

Radiation
Yes
No

•   Number in parentheses is the percentage of participants in this category (%)
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Telomere Length Measured by MMqPCR
Of the total 72 women in this study, the quality of DNA from one patient did not meet
quality control standards. Therefore, average genomic telomere lengths (which were assessed by
the T/S ratio) were estimated for 71 study participants at all five time points using MMqPCR
methodology. To determine if there was a potential association between telomere length at
baseline and age, a Pearson’s correlation was calculated. As expected, based on previous studies
showing that telomere length is inversely correlated with age in the general population, a
significant negative correlation between the participants’ age and their average genomic telomere
length was observed at baseline (r = -0.37, p = 0.001), as shown in Figure 2.
Given that telomere length has been associated with the frequency of spontaneous (and
induced) chromosomal abnormalities in a variety of human cell types and health conditions
(Leach et al., 2004), the T/S ratio values were compared to micronucleus/micronuclei (MN)
frequencies (micronuclei are an indicator of chromosomal instability), at each time point using a
Pearson correlation test. However, no significant associations were observed between mean
telomere length and MN frequency [visit 1 T/S ratio and visit 1 MN frequency (r = -0.084, p =
0.491); visit 2 T/S ratio and visit 2 MN frequency (r = -0.054; p = 0.659); visit 3 T/S ratio and
visit 3 MN/ frequency (r = -0.016, p = 0.896); visit 4 T/S ratio and visit 4 M/N frequency (r = 0.047, p = 0.708); visit 5 T/S ratio and visit 5 MN frequency (r = -0.203, p = 0.197)].
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Figure 2: Association between age and average genomic telomere length at baseline. Each
circle (•) represents a study subject. Average genomic telomere length at baseline was negatively
correlated with age (r = -0.37, p = 0.001).
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In addition to the assessment of MN frequency, we also investigated the relationship between
telomere length change and other treatment, demographic variables and PNS by fitting the data
into a mixed effects linear regression model (Table 6). Potential predictive variables evaluated
included visit, age, race, income, tumor grade and stage, receiving Herceptin, having
neoadjuvant treatment, tumor characterization as luminal A, luminal B, triple negative or HER2
positive and PNS including anxiety, depression, pain, fatigue, sleep disturbance and stress. The
final optimized model identified age (p = 0.004), race (p = 0.019) and the type of chemotherapy
treatment (p = 0.044) as having a significant predictive association with mean telomere length
(Table 6). For the racial groups, the average genomic telomere lengths were higher in African
American participants (mean = 1.661; s.e. = 0.087) compared to Caucasian participants (mean =
1.420; s.e.= 0.061) (Table 6). The study visit time was not found to be a significant predictor of
telomere length (p = 0.666). However, the shortest telomere lengths tended to be observed at
visit 3 (p = 0.41) (where a subset of patients were on radiation treatment), with values by 12
months and 24 months following the initiation of chemotherapy tending to be comparable to
values at baseline (Figure 3). While visit alone was not predictive of mean telomere length, the
type of chemotherapy used in treatment was found to be a significant predictor of telomere
length (p = 0.044), with the subset of women receiving TAC treatment having significantly
higher mean telomere lengths (mean = 1.681; s.e. = 0.074) than the women receiving TCH
(mean = 1.366; s.e. = 0.103) chemotherapy regimens (p= 0.036) (table 5). However, women
receiving TC treatment were not significantly different from TCH (p= 0.272) or TAC (p= 0.535)
groups. Other variables screened were found to have no significant prediction of telomere length
(Table 6).
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Figure 3: Vlues for MMqPCR based telomere length over time. Average genomic telomere
lengths are shown at baseline (visit 1) (mean= 1.542, s.e.= 0.062), mid-chemo (visit 2) (mean=
1.534, s.e.= 0.070), visit 3 (mean= 1.489, s.e.= 0.064). visit 4 (mean= 1.584, s.e.= 0.068) and
visit 5 (mean= 1.583, s.e.= 0.070).
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Table 6: Mixed Effects Linear Model Fitting Assessment of Predicative Associations of
Variables with qPCR Telomere Length

Base Model1
Variable

p-value

Visit

0.666

Final Model2
Least Squares
Mean

Std.
Error

Age*

0.004

Race*

0.019

African Americans

1.661

0.087

Caucasians

1.420

0.061

Income

0.083

Chemotherapy*

	
  

p-value

0.044

TAC

1.681

0.074

TC

1.575

0.088

TCH

1.366

0.103

Chemotherapy by visit

0.259

Radiation

0.641

Radiation by visit

0.271

Stage

0.148

Grade

0.954

Herceptin Yes/No

0.857

Neoadjuvant

0.506

Luminal A

0.891

Luminal B

0.529

Triple negative

0.997

49	
  

	
  
HER2 positive

0.350

Anxiety

0.461

Depression

0.633

Pain

0.946

Fatigue

0.759

Sleep disturbance

0.825

Stress

0.760

1

The base model, which was determined by the study design, was: telomere length = Visit +
Chemotherapy (3 types) + Radiation therapy +Visit by chemotherapy3 + Visit by Radiation
therapy3 with the study subject being the random effect
2

The final model reflects variables that remained significantly associated with telomere length
after stepwise removals
3

The visit by chemotherapy and visit by radiation therapy variables allowed these values to
differ across time points
* Variables significantly predicative of telomere length
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Telomere Length Quantified Using Chromosome-Specific FISH
Of the 72 women included in this study, blood specimens obtained from 22 patients did not
yield metaphases from either baseline and/or the mid-chemo specimen. Therefore, chromosomespecific telomere lengths were compared for 50 subjects. In order to determine if there was a
change in the telomere intensity value of each chromosomal arm (p arm and q arm) from
baseline (visit 1) to mid-chemo (visit 2) within and across study participants, the percent change
in telomere intensity values was calculated. Negative values reflected a decrease in telomere
length at mid- chemo compared to baseline; a zero value reflected no change in telomere length;
and a positive value reflected an increase in telomere length at the mid-chemo compared to
baseline time points. The percent change values for telomeres on each chromosomal arm (short
arm and long arm) and each study participant is graphically represented using a heat map (Figure
4). Interestingly, while we observed that the majority of telomeres showed attrition, a small
subset of telomeres showed increases in length as shown in Figure 5.

In addition to calculating percent changes, we compared telomere fluorescent intensities of
the short and long arm of the 23 chromosomes (1-22 and X) between baseline and mid-chemo
using a paired t-test. Significantly shortened telomeres were found on 1p (p = 0.022), 5q (p =
0.041), 7q (p = 0.025), 9q (p = 0.045), 18q (p = 0.002), 20p (p = 0.020), 21q (p = 0.040) and 22p
(p = 0.025), with marginal significance for decreases of telomere length being observed for 6p,
6q, 7p, 8p, 9p, 10q, 13p, 13q, 14q, 17q, 18p, and 22q (Table 7).
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Figure 4: Heat map representation of percent changes in telomere intensity values from
baseline to mid-chemo. Each column represents a chromosomal arm and each row represents a
study participant [Study Identifier (SID)]. The legend shows the percent change, with decreases
in telomere length represented by negative values (shown in blue tones), whereas increases in
telomere length are represented by positive values (shown in red tones).
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Figure 5: Mean of chromosome-specific telomere lengths in all study participants (n = 50).
The average of the difference in telomere length from baseline to mid-chemo is shown for each
chromosomal arm.
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Table 7: A Comparison of Chromosome Intensity Values Between Baseline and MidChemo Specimens in 50 Women with Early Stage Breast Cancer
Chromosome
Baseline
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X

	
  

Mean
4.085
5.291
6.054
4.349
5.107
5.452
4.419
5.222
5.429
5.326
4.587
4.636
4.858
4.827
4.544
3.920
4.106
5.188
3.997
4.979
5.060
4.902
5.240

SD
1.702
2.148
2.128
1.903
2.074
2.171
1.868
2.017
2.080
2.117
1.897
1.909
1.963
2.069
1.969
1.796
1.765
2.141
1.791
2.060
2.124
2.016
2.103

Short Arm
Mid-Chemo
Mean
3.556
4.787
5.579
3.947
4.749
4.866
3.935
4.663
4.879
4.967
4.204
4.194
4.340
4.432
4.208
3.484
3.717
4.596
3.631
4.282
4.543
4.239
4.893

SD
1.767
2.184
2.233
1.856
2.072
2.118
1.763
1.970
2.142
2.188
1.994
2.093
1.999
2.256
1.976
1.590
1.714
2.056
1.686
1.977
1.955
1.949
2.149

Baseline
Mean of the difference
-0.529
-0.504
-0.475
-0.402
-0.358
-0.586
-0.484
-0.559
-0.550
-0.359
-0.383
-0.442
-0.518
-0.395
-0.336
-0.436
-0.389
-0.592
-0.366
-0.697
-0.517
-0.663
-0.347

p-value
0.022
0.102
0.144
0.160
0.241
0.084
0.058
0.054
0.062
0.228
0.173
0.145
0.064
0.165
0.218
0.119
0.150
0.051
0.149
0.020
0.108
0.025
0.236
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Mean
5.292
4.084
5.148
5.588
4.811
5.180
5.182
4.396
3.781
4.621
5.123
4.659
5.331
4.754
5.193
4.305
4.118
5.496
4.580
4.187
4.413
4.058
4.850

SD
2.058
1.732
2.238
2.155
2.135
2.119
2.107
1.993
1.768
2.004
2.110
1.958
2.202
2.135
2.117
1.869
1.815
2.098
1.887
1.805
1.867
1.795
2.075

Long Arm
Mid-Chemo
Mean
4.955
3.718
4.714
5.204
4.186
4.614
4.449
4.052
3.322
4.170
4.693
4.216
4.809
4.275
4.737
3.938
3.714
4.620
4.135
3.743
3.897
3.610
4.589

SD
2.228
1.793
2.108
2.173
2.029
2.134
2.058
2.105
1.731
1.935
2.201
2.009
2.164
1.952
2.170
1.955
1.782
1.877
1.901
1.949
1.740
1.827
2.199

Mean of the difference
-0.337
-0.366
-0.434
-0.384
-0.625
-0.566
-0.733
-0.344
-0.459
-0.451
-0.430
-0.443
-0.522
-0.479
-0.456
-0.367
-0.404
-0.876
-0.445
-0.444
-0.516
-0.448
-0.261

p-value
0.272
0.155
0.158
0.195
0.041
0.069
0.025
0.198
0.045
0.093
0.134
0.142
0.090
0.069
0.111
0.167
0.099
0.002
0.135
0.134
0.040
0.090
0.385

	
  

In agreement with the paired t-test results, a mixed effects model adjusted for age showed
that there is a significant shortening in chromosome-specific telomere length from baseline to
mid-chemo on chromosomal arms 1p (p = 0.022), 5q (p = 0.041), 7q (p = 0.025), 9q (p = 0.045),
18q (p = 0.002), 20p (p = 0.020), 21q (p = 0.040) and 22p (p = 0.025) (Table 8).

To further assess the association between chemotherapy treatment on telomere lengths, a
fixed effects model, adjusted for age, was also fit to the chromosome-specific data. The type of
chemotherapy treatment was observed to be predictive of telomere lengths on 32 of the 46
chromosomal arms (Table 9), with participants receiving TAC chemotherapy treatment have
numerically higher mean telomere lengths on those chromosomes compared to study participants
receiving TC or TCH treatment (Table 9).

To determine if there was an association between telomere length and PNS we included
“total” values for the symptoms of anxiety, depression, pain, fatigue, sleep disturbance and stress
into the mixed effect model, adjusted for age, to assess their predictive potential of chromosomespecific telomere length. Among all the PNS tested, pain (but no other symptoms) was found to
be a significant negative predictor of telomere lengths (higher pain; shorter telomeres) for 5q (p
= 0.040), 8p (p = 0.047), 13p (p = 0.019), 20p (p = 0.036), 22p (p = 0.035), Xp (p = 0.014), Xq
(p = 0.039) (Table 10).
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Table 8: Mixed Effects Linear Model Fitting Assessment of Visit as a Significant
Predicative variable of Chromosome-Specific Telomere Length

Chromosome Arm

	
  

Least Square
Mean at Baseline

Least Square Mean
at Mid-Chemo

Std.
Error

p-value

1p

3.632

3.103

0.264

0.022

5q

4.428

3.803

0.330

0.041

7q

4.757

4.024

0.331

0.025

9q

3.376

2.917

0.217

0.045

18q

5.078

4.204

0.311

0.002

20p

4.635

3.938

0.320

0.020

21q

3.954

3.438

0.274

0.040

22p

4.499

3.835

0.305

0.025
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Table 9: Mixed Effects Linear Regression Model Fitting Assessment of Predictive
Association of Chemotherapy Type with Chromosome-Specific Telomere Length

	
  

Chromosome
Arm

TAC Least Square
Mean

TC Least Square
Mean

TCH Least Square
Mean

P-value

1p

4.346 (0.251)

2.944 (0.451)

2.813 (0.501)

0.004

1q

5.642 (0.314)

4.016 (0.564)

4.433 (0.626)

0.028

2p

5.602 (0.315)

3.929 (0.565)

4.174 (0.628)

0.017

2q

4.247 (0.263)

3.125 (0.473)

3.486 (0.526)

0.094

3p

6.252 (0.319)

4.671 (0.574)

5.508 (0.637)

0.059

3q

5.488 (0.317)

3.853 (0.570)

4.051 (0.634)

0.020

4p

4.475 (0.280)

3.671 (0.502)

3.436 (0.558)

0.157

4q

5.876 (0.326)

4.425 (0.586)

4.689 (0.651)

0.059

5p

5.451 (0.295)

3.696 (0.531)

4.376 (0.589)

0.014

5q

4.590 (0.309)

3.682 (0.556)

3.714 (0.618)

0.064

6p

5.698 (0.298)

4.028 (0.536)

4.417 (0.596)

0.015

6q

5.383 (0.312)

3.835 (0.561)

4.279 (0.623)

0.039

7p

4.598 (0.269)

3.465 (0.484)

3.383 (0.538)

0.043

7q

5.335 (0.305)

3.673 (0.549)

4.163 (0.609)

0.022

8p

5.453 (0.288)

3.821(0.518)

4.301 (0.575)

0.016

8q

4.685 (0.312)

3.252 (0.561)

3.593 (0.623)

0.056

9p

5.664 (0.314)

4.201 (0.564)

4.304 (0.627)

0.034

9q

4.037 (0.259)

2.581 (0.465)

2.821 (0.517)

0.012

10p

5.729 (0.313)

4.114 (0.562)

4.107 (0.624)

0.013

10q

4.821 (0.299)

3.726 (0.537)

3.531 (0.597)

0.070

11p

4.791 (0.292)

3.639 (0.524)

3.758 (0.582)

0.090

11q

5.413 (0.327)

4.152 (0.587)

3.837 (0.653)

0.045

12p

4.890 (0.287)

3.289 (0.515)

3.918 (0.572)

0.023

12q

4.838 (0.289)

3.674 (0.520)

3.791 (0.578)

0.083

13p

5.093 (0.289)

3.422 (0.519)

4.096 (0.576)

0.018

13q

5.599 (0.323)

4.146 (0.580)

4.111 (0.645)

0.033

14p

5.221 (0.314)

3.349 (0.565)

3.864 (0.628)

0.010
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14q

5.000 (0.312)

3.487 (0.561)

3.856 (0.623)

0.041

15p

4.885 (0.285)

3.131 (0.512)

3.896 (0.569)

0.012

15q

5.535 (0.318)

3.823 (0.571)

4.112 (0.634)

0.017

16p

4.064 (0.237)

2.993 (0.426)

3.137 (0.473)

0.049

16q

4.614 (0.281)

3.126 (0.504)

3.398 (0.560)

0.020

17p

4.282 (0.250)

3.083 (0.449)

4.464 (0.499)

0.051

17q

4.265 (0.276)

3.126 (0.496)

3.507 (0.551)

0.110

18p

5.224 (0.322)

4.218 (0.578)

4.404 (0.643)

0.238

18q

5.556 (0.292)

4.058 (0.526)

4.310 (0.584)

0.024

19p

4.281 (0.248)

2.280 (0.445)

3.185 (0.495)

0.010

19q

4.852 (0.261)

3.232 (0.469)

3.786 (0.522)

0.009

20p

5.054 (0.300)

3.684 (0.539)

4.122 (0.599)

0.067

20q

4.430 (0.262)

2.917 (0.470)

3.414 (0.522)

0.015

21p

5.356 (0.278)

3.474 (0.500)

4.242 (0.555)

0.005

21q

4.700 (0.257)

3.121 (0.462)

3.267 (0.513)

0.004

22p

5.068 (0.282)

3.438 (0.506)

3.995 (0.562)

0.016

22q

4.269 (0.264)

3.086 (0.475)

3.028 (0.527)

0.031

Xp

5.518 (0.322)

4.320 (0.579)

4.190 (0.643)

0.077

Xq

5.237 (0.316)

3.834 (0.567)

3.756 (0.630)

0.032

* The standard error is shown in parenthesis
* Bold rows indicate significance (p ≤ 0.05)
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Table 10: Pain as a Significant Negative Predictor of Telomere Length

Parameter Estimate

Standard Error

p-value

1p

-0.165

0.099

0.103

1q

-0.196

0.124

0.121

2p

-0.127

0.126

0.319

2q

-0.146

0.105

0.170

3p

-0.185

0.127

0.151

3q

-0.182

0.126

0.156

4p

-0.131

0.112

0.248

4q

-0.185

0.130

0.160

5p

-0.188

0.117

0.115

5q

-0.120

0.120

0.040

6p

-0.131

0.120

0.279

6q

-0.222

0.122

0.076

7p

-0.197

0.105

0.069

7q

-0.119

0.123

0.335

8p

-0.229

0.112

0.047

8q

-0.195

0.123

0.122

9p

-0.242

0.122

0.054

9q

-0.164

0.102

0.116

10p

-0.199

0.124

0.114

10q

-0.202

0.118

0.093

11p

-0.177

0.116

0.133

11q

-0.203

0.129

0.123

12p

-0.175

0.113

0.130

12q

-0.215

0.113

0.064

13p

-0.267

0.110

0.019

13q

-0.197

0.128

0.131

Chromosome
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14p

-0.158

0.126

0.215

14q

-0.189

0.124

0.133

15p

-0.186

0.112

0.106

15q

-0.216

0.125

0.090

16p

-0.168

0.093

0.077

16q

-0.204

0.110

0.070

17p

-0.164

0.099

0.103

17q

-0.212

0.108

0.055

18p

-0.252

0.125

0.051

18q

-0.181

0.116

0.124

19p

-0.145

0.098

0.148

19q

-0.187

0.102

0.075

20p

-0.251

0.116

0.036

20q

-0.126

0.105

0.235

21p

-0.185

0.110

0.099

21q

-0.139

0.102

0.180

22p

-0.237

0.109

0.035

22q

-0.189

0.103

0.075

Xp

-0.311

0.122

0.014

Xq

-0.260

0.122

0.039

* Bold rows indicate significance (p ≤ 0.05)

	
  

60	
  

	
  

Chapter 5
Discussion
In this study we sought to measure telomere length in lymphocytes obtained from patients
who received chemotherapy for breast cancer using two different, but complementary, telomere
length assays. The first was a qPCR-based assay, which is considered a high throughput assay
with fast turn-around time that allows for the estimation of average genomic telomere length.
The second assay used was a chromosome-specific PNA-FISH assay, which allows for the
quantification of telomere lengths on each chromosomal arm, as well as the mean genomic
telomere length. The use of both assays provided a confirmatory opportunity for the results
discussed herein.

Consistent with the results of other investigators (Svenson et al., 2008, Wang et al., 2011),
baseline telomere lengths of the women in our study showed a significant inverse correlation
with age (older women had shorter telomeres). Furthermore, age was found to be a significant
predictor of telomere length in our study cohort. Telomere attrition is one of the several cellular
and molecular hallmarks contributing to the aging process and arises as a result of the end
replication problem (reviewed in Aubert & Lansdorp, 2008, Lopez-Otin et al., 2016). It is
thought that environmental and life-style related factors, such as smoking, exposure to pollution,
lower physical activity, psychological stress, and unhealthy diet also contribute to accelerating
telomere shortening and the ageing process via increased levels of inflammation and oxidative
burden (von Zglinicki, 2000, Cherkas et al., 2008, Cassidy et al., 2010, Barrett et al., 2015,
reviewed in Zhang et al., 2016). Furthermore, the sequence motif in human telomeres
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(TTAGGG), which have a triple guanine structure, is thought to make them particularly
susceptible to oxidative damage, with the repair of this oxidative damage being relatively
inefficient (Kawanishi, Hiraku & Oikawa, 2001, von Zglinicki, 2002).

Another demographic variable that was observed to be a significant predictor of mean
telomere length in our study cohort was race, with African Americans having longer mean
telomere lengths than Caucasians. This observation has been reported in other studies
investigating the relationship of race with telomere length in families with high and low risk of
cardiovascular disease (Hunt et al., 2008), as well as healthy individuals (Lynch et al., 2016).
Interestingly, in a case-control study on the association between leukocyte telomere length and
breast cancer risk, Zheng, et al. (2010) reported higher mean telomere lengths in African
Americans compared with Caucasians in newly diagnosed, pretreatment cases with breast
cancer, but not in matching controls (Zheng et al., 2010). The mechanism(s) underlying this
racial difference in telomere length is/are not well understood. One reason might be that healthy
African Americans were found to have lower oxidative damage levels and lower plasma levels of
antioxidants than Caucasians, suggesting that there might be race-related differences in the
cellular processes involved in oxidative-related DNA damage and repair (Huang, Helzlsouer,
&Appel, 2000, Watters et al., 2007, Watters, Satia, & Kupper, 2008). Alternatively, although the
mixed effect model used in this study allowed adjusting for age, the inter-relatedness of human
epidemiology variables increases the possibility for the presence of an effect from other
confounding factors. Thus, one cannot fully rule out the possibility that the age distribution in
our study cohort may have contributed to this association with race since the African American
participants were significantly younger than the Caucasians (Aboalela, et al., 2015). Moreover,
our model was not adjusted for other potential confounding factors that have been demonstrated
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to be associated with higher oxidative stress or short telomere length, including (but not limited
to) body mass index (BMI), smoking status, alcohol consumption, physical activity and the
intake of antioxidants (Watters, Satia, & Kupper, 2008, Muezzinler, Zaineddin, & Brenner, 2013,
Muezzinler et al., 2015, Muezzinler et al., 2016).

The main aim of this study was to test our hypothesis that chemotherapy contributes to
chromatin breakage within the telomere, thereby leading to telomere shortening in women with
early stage breast cancer. Using the data from the qPCR-based method, we did not observe a
significant change in mean telomere lengths across the 5 time points in this 2-year longitudinal
study. Although telomere length in epidemiological studies is most often evaluated as a single
mean genomic measure, investigators have shown that there is heterogeneity between
chromosomes (and between individuals) for telomere length, as well as variability between
telomeric arms (short arm compared to long arm) within a chromosome (Lansdorp et al., 1996,
Hemann et al., 2001, Gilson & Londono-Vallejo, 2007, Xu et al., 2013). Moreover, the results of
a number of reports have suggested that telomere shortening does not occur at an equal rate
among all chromosomal arms and that chromosomal arms with the shortest telomeres are most
frequently involved in end-to-end fusions and genomic instability (Hemann et al., 2001, Soler et
al., 2005). However, the qPCR-based mean telomere length assay cannot fully detect
chromosome-specific heterogeneity (e.g. presence of relatively long telomeres could mask the
presence of a sub-set of short telomeres present on specific chromosomal arms), nor can it
capture information about telomeres that are extremely short/missing. Therefore, given the above
mentioned limitations of the qPCR methodology, we elected to also measure chromosomespecific telomere lengths.
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By exploiting the strength of our longitudinal study design for this chromosome-specific
comparison, we were able to quantify changes in telomere length within a study subject (thereby
reducing the impact of person-to-person variations in telomere lengths). The results of this
analysis showed significant telomere attrition for a subset of 8 different chromosomal arms;
specifically, 1p, 5q, 7q, 9q, 18q, 20p, 21q, and 22p. There are very few investigators who have
evaluated chromosome-specific telomere lengths as they relate to cancer, with these few studies
being concentrated on the relationship between chromosome-specific length and the risk of
acquiring breast cancer or esophageal cancer (Table 11) (Zheng et al., 2009, Xing et al., 2009,
Zheng et al., 2011). Therefore, our observation is considered an initiating step for investigating
possible mechanisms responsible for these chromosomes to be preferably shortened during/after
treatment for breast cancer.

Two main factors that have been conjectured to drive telomere length shortening, beside the
end replication problem, are inflammation and oxidative DNA damage (von Zglinicki, 2002).
Our observation that the type of chemotherapy received was predictive of telomere length is
consistent with these canonical influences. There are several potential mechanisms that could
explain our observed association between chemotherapy and telomere length. Genotoxic drugs
may have an intrinsic role in telomere shortening given that telomeres have been shown to be
particularly susceptible to oxidative damage and since repair of this damage is relatively
inefficient in telomeres (von Zglinicki, 2000, von Zglinicki 2002, Shen et al., 2009, Fumagalli et
al., 2012).

In addition to exerting their therapeutic effect through direct DNA damage, chemotherapeutic
drugs that are frequently used in treating breast cancer have an indirect negative impact on
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telomeres by affecting members of the shelterin complex. Among the six shelterin components,
TRF2 and POT1 were found to be the most important in ensuring chromosome end protection by
preventing ATM and ATR dependent checkpoint activation (van Steensel, Smogorzewska, & de
Lange, 1999, Karlseder et al., 1999, Denchi & de Lange, 2007, Guo et al., 2007). Moreover,
doxorubicin has been found to reduce the expression of POT1 and TPP1, which in turn could
alter the telomere structure and compromise its stability, thereby promoting telomere shortening
(Li et al., 2012, Kato et al., 2013).

Another class of chemotherapeutic drugs frequently used in treating breast cancer is Taxanes,
which act through mitotic inhibition (Janssen & Medema, 2011). Although the exact mechanism
for the induction of cell death upon mitotic inhibition is unknown, it is proposed that prolonged
mitotic inhibition, in vitro, has the ability to dissociate TRF2 from telomeres and activate a DNA
damage response, thereby providing a mechanism for telomere shortening through telomere
dysfunction. (Hayashi et al., 2012, Lu et al., 2013).

In addition to showing that overall chemotherapy was predictive of telomere length, we also
showed that there were differential effects based on the type of chemotherapy used in treatment,
with telomere lengths of women receiving TAC regimens being significantly different from
those receiving TCH regimens. Adriamycin (also known as doxorubicin) is a member of the
anthracycline class of chemotherapeutic agents. Anthracyclines are thought to shorten telomeres
through direct DNA damage by free radical formation (von Zglinicki, 2000, Quiles et al., 2002,
Thorn et al., 2011). Another proposed mechanism of action for anthracyclines is the inhibition of
DNA repair enzymes, particularly topoisomerase II, which may contribute to telomere
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shortening through further accumulation of DNA damage (Table 12) (Elmore et al., 2002,
Maccormick, 2006, Thorn et al., 2011, Buttiglieri, et al., 2011).

While a subset of women receiving TAC had shortened telomeres, we also observed the
unexpected result that overall patients on the TAC regimen had longer mean telomere lengths
when compared to patients undertaking TCH regimens. Similarly, the model used for the
analysis of the chromosome-specific telomere data showed that patients on the TAC regimen had
numerically higher telomere lengths than patients undertaking TC or TCH. One of the key
components to the TAC regimen that is not present in the TCH regimen is the presence (or
absence) of Adriamycin, which has been shown to have several cytotoxic effects and has been
associated with telomere shortening, as noted above. When coupling the knowledge of the
cellular effects of Adriamycin with our study results, they initially seemed to be paradoxical.
However, a plausible explanation could be that ALT is activated as a rescue mechanism of the
extensive DNA damage caused by TAC. From experiments on immortalized human cell lines
that utilize the ALT mechanism for telomere length maintenance, it is hypothesized that ALT
involves homologous-recombination (HR) mediated DNA copying of telomeric DNA (Dunham
et al., 2000, Conomos, Picket & Reddel, 2013). One can speculate that telomeres become
uncapped due to excessive shortening; presumably because they are no longer able to bind
sufficient shelterin proteins (Denchi & de Lange, 2007, Sfeir & de Lange, 2012). Given the role
of TRF2 and POT1 in suppressing HR-mediated DNA damage repair (Rai et al., 2016), it is
reasonable to speculate that depletion of both proteins as an effect of Adriamycin would allow
the activation of ALT through HR-mediated DNA repair.
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One of the fundamental questions addressed in this study was the association between
telomere length and PNS in patients treated for early stage BC. While no statistically significant
associations between PNS and overall mean telomere length (using a qPCR method) were
observed, our chromosome-specific telomere length data indicated that pain is a significant
negative predictor of the length of the telomeres localized to 5q, 8p, 13p, 20p, 22p, Xp and Xq.
Standard medical interventions of breast cancer (i.e., surgery, chemotherapy and/or radiotherapy)
have pain as a common consequence (Starkweather, Lyon, & Schubert, 2011, Ferreira et al.,
2015). The relationship between proinflammatory cytokines, including (but not limited to) CRP;
TNFα; IL-2; IL-6; IL-8; IL-10, and pain has been established in many clinical conditions
associated with inflammation, with higher levels of these inflammation markers being associated
with greater pain intensity/sensitivity (reviewed in DeVon et al., 2014). Excessive telomere
shortening arising as a result of oxidative stress mediated by increased inflammatory activity
from the cancer itself, or chemotherapy, may lead to increased replicative senescence. Given that
lymphocytes with shortened telomeres and senescent cells hypersecrete proinflammatory
cytokines, particularly IL-6 (Efross, 2009), accelerated telomere attrition may play a role in the
development of pain in our study cohort by contributing to the increased levels of IL-6.
Furthermore, since chronic pain represents a physiological stressor, the associated increase in
pro-inflammatory cytokines, upon activation of the stress pathway, may also be considered as a
potential pathway for increased telomere shortening, thereby creating a cycle of telomere
shortening from high levels of inflammation and increased pain sensation from increased
telomere attrition-mediated cellular senescence.

Given that IL-6 molecules are not retained for a long period of time, the above proposed
mechanisms may be an initiating step, with telomere biology playing a role in the persistence of
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pain in patients with breast cancer into survivorship. However, the nature of the association
between pain and telomere length is not clear. It is possible that this relationship is merely
correlative, with the telomere length serving as a “canary in a coal mine” type observation that
enables one to document that a biologically relevant change has occurred. Alternatively, it has
been speculated that telomere length shortening could initiate epigenetic changes in genes that, in
turn, contribute to acquired phenotypes. These epigenetic changes could arise as a result of the
telomere position effect (TPE), which involves the spreading of a heterochromatic conformation
of the DNA juxtaposed to the telomere to silence subtelomeric genes, with this phenomenon
functioning in relation to telomere length. In a study of a complex-age associated disease,
facioscapulohumeral muscular dystrophy (FSHD), TPE was shown to extend at least 100 kb into
the subtelomeric region of chromosome 4q where the gene that is linked to the disease is upregulated by an effect of telomere shortening (Stadler et al., 2013). While the biological cascade
of events is not known, one could speculate that a change in the chromatin structure of the
subtelomeric region driven by telomere attrition in any of the chromosomal arms identified in
this study could alter gene expression thereby contributing to the “biological remembering” of
PNS.

The quantification of (MN) frequencies in lymphocytes of patients with cancer has been used
extensively as a biomarker of chromosomal damage and genomic instability. Being part of a
larger study, we had access to MN frequencies scored in lymphocytes obtained from our study
cohort at the five time points, as indicated earlier. Given that telomeric attrition has been
associated with an increased frequency of chromosomal stability, we expected to see a negative
correlation between telomere length and micronuclei frequency (shorter telomeres leading to
higher MN levels). While negative relationships were observed between these variables, the
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correlations did not reach significance at the five time points tested. It is quite feasible that while
aberrations related to telomeric attrition following chemotherapy may arise, the majority of
chromosomal changes being induced by chemotherapy may occur at sites other than the
telomere, thereby reducing the association between telomere length and MN frequency.

Another variable lacking a significant predictive association with telomere length in our
study cohort is the tumor characteristics. Shorter telomeres in tumor tissue have been associated
with more aggressive subtypes, including luminal B, HER2 positive and triple negative tumors
(Heaphy et al., 2011), but little is known about the association of a patient’s leukocyte telomere
length based on her breast tumor molecular sub-group characterization. In a recent study,
Barczak, et al (2016) reported shorter telomere lengths in leukocytes derived from patients with
higher stage breast cancer compared to patients at an early stage of the disease, but found no
association between the histological cancer grade and leukocyte telomere length in patients with
early or advanced stage breast cancer. In this study, we also did not find tumor stage, or tumor
molecular sub-groups, to be predictive of lymphocyte telomere length. However, it is reasonable
to conjecture this lack of association between telomere length and tumor characteristics could be
due to the inclusion of only women with early stage breast cancer. Alternatively, leukocyte
telomere length may not be predictive of tumor telomere lengths.

The most prominent strength of our study is its longitudinal design that allowed for the
assessment of telomere length prior to chemotherapy, during active treatments and into
survivorship. Moreover, most studies on telomere dynamics are limited by focusing on
measuring average genomic telomere length using qPCR-based methodology. Our use of the
chromosome-specific assay enabled us to assess individual telomeres. However, this later assay
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is very labor intensive and expensive therefore, our assessment of telomere length using this
method was limited to only baseline and mid-chemo, which in turn limited our comparisons to
only two time points. Also, since high quality metaphases for the chromosome-specific assay,
could not be obtained from a subset of our study participants, the sample size was decreased for
this assay. Another limitation of this study was that our statistical analysis did not adjust the
mixed effect models for all possible confounders. Therefore, our observations may have been
affected by these confounders.

In summary, we showed that demographic factors significantly associated with telomere
shortening were age and race. Using our chromosome-specific assay, we also showed that
overall, telomere length in lymphocytes obtained from women treated for breast cancer is
shortened following the initiation of chemotherapy treatment and that the change in telomere
length (from baseline values) differs based on the type of chemotherapy used in treatment. We
also demonstrated that this shortening doesn’t affect all telomeres equally, with telomeres on
only a subset of chromosomal arms being most impacted. Lastly, our study showed that pain was
significantly related to telomere shortening in this study cohort.
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Table 11: Chromosome-Specific Telomere Length and Cancer Risk

Reference
Zheng et al., 2009

Study Sample

Method

Summary of Finding

Cases: 153 women with
breast cancer who have not
been treated with
chemotherapy or
radiotherapy

Q-FISH

Short telomere on
chromosome 9p is
strongly associate with
breast cancer risk

Controls: 159 age matched
healthy women
Zheng et al., 2011

Cases: 204 women with
breast cancer who have not
been treated with
chemotherapy or
radiotherapy

PNA-FISH

Short telomere length on
chromosomes 9p,15p, 15q
and Xp is associated with
breast cancer risk in premenopausal women

Controls: 236 age matched
healthy women
Xing et al., 2009

Cases: 94 untreated
patients with esophageal
cancer

STELA

Controls: 94 age, gender
and ethnicity matched
healthy subjects

Q-FISH= Quantitative Fluorescence In Situ Hybridization
PNA-FISH= Peptide Nucleic Acid Fluorescence In Situ Hybridization
STELA= Single Telomere Length Analysis
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Short telomere length on
chromosomes 17p and
12q play a more
prominent role in the
etiology of esophageal
cancer than 11q and 2p

	
  

Table 12: Studies on the Effect of Doxorubicin (Adriamycin) on Telomere Biology

Reference

Sample type

Study outcome

Elmore et
al., 2002

Mcf7 breast tumor cell line

Breast tumor cells treated with Adriamycin
require both functional p53 and telomere
dysfunction to exhibit a senescence phenotype

Mitchell
et al.,
2010

LiSa-2 ALT positive cell line derived
from a poorly differentiated
pleomorphic liposarcoma

Cell lines sensitivity to doxorubicin correlated to
topoisomerase 2A (TOP2A) gene expression, with
LiSa-2 cell line showing the highest sensitivity to
doxorubicin and the highest expression of TOP2A
followed by LS2 cell line

LS2 cell line derived from ALTpositive pleomorphic liposarcoma
SW872 cell line expressing expressing
both components of telomerase
Buttiglieri
et al.,
2011

Mesenchymal stem cells derived from
normal human bone marrow

Telomere loss following treatment with
doxorubicin that was also associated with defects
in proliferation and differentiation

Li et al.,
2012

T-lymphocytes isolated from buffy
coats of healthy individuals with
stimulated telomerase activation

Rapid loss of telomeric DNA sequence, coupled
with down-regulation of telomerase activity,
repression of hTERT, TPP1 and POT1 (members
of the shelterin complex) expression in Tlymphocytes and fibroblasts treated with
doxorubicin resulting in telomere dysfunction in a
high fraction of cells

Normal human lung fetal fibroblasts
representing telomerase deficient cells

	
  

SW872 cell line showed showed the lowest
sensitivity to doxorubicin and the lowest
expression of TOP2A

Kato et
al., 2013

Human cervical carcinoma cell line
(HeLa), human normal fibroblast cell
line (WI-38), human osteosarcoma cell
lines (U-2-OS and Saos-2)

TRF1 and POT1 (members of the shelterin
complex) mRNA levels were commonly downregulated in both cancerous and normal cell lines
following treatment with doxorubicin. On the
other hand, RAP1 was up-regulated in a timedependent manner in 2-OS cells only

Sanoff et
al., 2014

33 women with early stage breast
cancer (I-III) who were receiving
doxorubicin, cychlophosmaide and
taxane

Telomere length was measured before
chemotherapy and 12 months after chemotherapy,
with no significant change observed
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Chapter 6
Conclusion and Future Directions

Concluding Remarks
Telomere biology plays a critical role in regulating cellular life span, aging and genomic
instability. Therefore, telomere length has emerged as a prominent molecular marker of adverse
health outcomes, such as breast cancer, which is among the most prevalent diseases worldwide
but also one that has a high survival rate because of continuous advancements in detection and
treatment strategies. Telomere length alterations in patients with breast cancer have been
evaluated extensively as a diagnostic marker in breast tissue. However, research involving
measuring telomere length in peripheral blood lymphocytes have focused primarily on
investigating the potential link between telomere length and the risk of developing breast cancer.
Clearly, there is a lack in the literature for studies investigating the relationship between genetic
changes, particularly telomere attrition and the development and persistence of PNS under the
influence of chemotherapy in patients with breast cancer.

Future Directions
This work was designed to assess telomere length in women with early stage breast cancer
who were treated with chemotherapy, with the goal of improving our understanding of the role
biological events play in the development and persistence of PNS. We have successfully
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identified significant shortening in telomere length following the administration of chemotherapy
in specific chromosomal arms. Furthermore, we have identified that patients in our study cohort
having shorter telomere length on particular chromosomal arms reported higher pain intensity.
Mammalian telomeric regions are enriched in signatures of heterochromatin including
hypermethylation (Benetti, Garcia-Cao & Blasco, 2007). The heterochromatic signature of the
telomeric region induces a position effect by spreading into the subtelomeric region as a function
of length (Robin et al., 2014). We therefore, suspect that chromosomes showing significant
telomere shortening may have an altered methylation profile in the subtelomeric region. This
may in turn change the expression of genes associated with PNS if present. As mentioned earlier,
this study is part of a larger study in which genome-wide methylation patterns were assessed
using the 450K HumanMethylation Chip at baseline and mid-chemo time points. The
methylation data could be used to determine if the distribution of sites showing methylation
alterations from baseline to mid-chemo are more heavily localized to the subtelomeric regions of
the telomeres that were showing significant shortening or the telomeres associated with pain. A
change in the cell’s methylation pattern(s) could have changed the expression of genes
associated with pain, thereby allowing the biological remembering of this side effect into
survivorship. Thus, we have already initiated additional studies to evaluate the possible presence
of a relationship between methylation patterns and telomere length in this study cohort.

Interestingly, although not significant, a subset of our participants showed both shortening
and lengthening of telomeres. This caught our attention as to what mechanism was responsible
for this observation? The absence or insufficient amount of telomerase in adult somatic cells,
points toward ALT as a plausible mechanism for increases in telomere lengths in our cohort.
Support for this hypothesis is derived from the proposed effect of chemotherapeutic drugs on
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different members of the shelterin complex which in turn could facilitate ALT through HR
mediated DNA repair. To further investigate this hypothesis, we intend to determine ALT status
by checking for the presence of telomere-sister chromatid exchange (T-SCE), which can be
detected using chromosome-orientation Fluorescence In Situ Hybridization (CO-FISH) on
metaphase spreads obtained from the study participants. This technique involves culturing cells
for a single replication cycle with the incorporation of the thymidine analog 5-bromo-2’deoxyuridine (BrdU) for it’s incorporation into the newly synthesized DNA strand and
subsequent destruction through nuclease digestion. This leaves the template strand intact for
FISH with telomere strand probes that can indicate the occurrence of a recombination event
between sister chromatids (Bailey et al., 2001, Vera et al., 2008). Furthermore, the presence of
telomere lengthening shown in our results could be also be addressed by determining the
existence of associations between telomere length and different healthy life style behaviors (such
as consuming a healthy diet, regular physical activity, practicing meditation), which have been
associated with longer telomere lengths in several studies. Careful analysis of these variable that
were obtained from our study cohort could aid in teasing apart the telomere lengthening
observation.

The influence of inflammatory markers and oxidative stress on telomere length and their
close association with PNS could provide another direction for expanding upon this study.
Increased cell turnover and replicative senescence negatively affect telomere length. Gene
expression levels of a classical marker of cellular senescence, CDKN2A (also known as p16),
IL-6 and IL-8, as well as measures of a wide range of proinflammatory cytokines, including IL6, were obtained from our study cohort. Therefore, our future studies will involve investigating
the potential correlation between these variables and telomere length would provide a plausible
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explanation for the observed telomere shortening in lymphocytes of patients with early stage
breast cancer.
To the best of our knowledge, this is the first study to provide insights into the effect of
chemotherapy on telomere length and their relationship with adverse side effects experienced in
patients with breast cancer over a period of 2 years. If confirmed and expanded upon in future
studies, these observations would be important for the recognition of lymphocyte telomere length
as a biomarker for the identification of women who are at an increased risk of developing PNS
and potentially designing therapeutic and intervention strategies that will be most effective in
alleviating the adverse side effects in BC survivors and for ultimately improving their quality of
life.
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